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Abstract 
Alcohol consumption and excess body weight create a major burden for modern health care. 
Both heavy drinking and obesity lead to derangements in liver function and increased oxidative 
stress; however, little is still known about the early-phase effects of ethanol intake and adiposity. 
 
The relationships between alcohol consumption, body mass index (BMI) and various 
laboratory  markers  (e.g.,  alanine  and  aspartate  aminotransferases  (ALT,  AST)  and  albumin  as  
markers of liver status, uric acid reflecting the status of oxidative stress, and Ȗ-glutamyl-
transferase (GGT) and ferritin being associated with both liver function and oxidative stress) 
were studied here in a large number of volunteers originally recruited by the NORIP survey for 
establishing common reference intervals in Nordic countries. The population consisted of 
apparently healthy abstainers and moderate drinkers (1–21 measures of alcohol/week, 75% of 
men, 62% of women), and also included subjects who were overweight (BMI 25–30 kg/m2, 41% 
of men, 22% of women) or obese (BMI >30 kg/m2, 4% of both men and women). In addition, 
the present study included a group of heavy drinkers who were devoid of liver disease. The dose-
response effects of ethanol and adiposity and their interactions on marker levels were assessed in 
the categories of drinking habits and BMI. The impacts were also evaluated by calculating the 
reference limits from different subpopulations and by comparing them with the widely used 
NORIP recommendations, which have been determined from the total survey population. 
 
The levels of serum ALT and GGT were significantly different between male moderate 
drinkers and abstainers, whereas AST, albumin and ferritin in men and the markers in women 
only differed between heavy drinkers and abstainers. When the BMI was included in the 
analyses on liver enzymes (ALT, AST, GGT), activities increased as a function of body weight 
throughout the BMI scale. The activities were further higher in moderate drinkers than in 
abstainers of the corresponding BMI. Some observations also suggested an interaction between 
the effects of the subject’s drinking habits and BMI on these enzymes, but the results of the 
statistical  tests  were  not  significant.   For  uric  acid,  the  concentrations  were  similarly  higher  
across the categories of BMI, and higher in male moderate drinkers than abstainers. The 
calculations of reference limits revealed that especially in men, a substantial increase has been 
introduced into the currently recommended limits by moderate drinking and excess body weight. 
The calculated upper reference limits from normal weight male abstainers for ALT were 50 U/l 
(while the current recommendation is 70 U/l), and for GGT 44 U/l in those <40 years (80 U/l) 
and 69 U/l in those 40 years (115 U/l). 
 
It may be concluded that moderate drinking and an increased BMI have notable effects on 
markers of liver function and oxidative stress at the population level. These should be recognized 
in order to improve the clinical value of such measurements for diagnostic purposes and for 
preventive medicine. 
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1. Introduction 
Alcohol consumption, excess body weight, and related health problems have increased rapidly in 
our society (Färkkilä 2009). More than half of the Finnish population is currently overweight or 
obese and the per capita ethanol consumption has increased fourfold since the 1960s (Peltonen et 
al. 2008, Figure 1). Most recently, alcohol consumption has decreased for three consecutive years 
in conjunction with increases in alcohol taxation in 2008 and 2009 (after a relaxation of taxation 
in 2004 and a sharp increase in consumption). Similarly, the increase of adiposity also seems to 
have  subsided  if  assessed  in  terms  of  the  mean  conscript  weight  (Figure  1).  Nevertheless,  the  
degree of ethanol intake and extra weight remains very high, and these need attention. 
 
The health of the liver is affected by both ethanol consumption and excess body weight. With 
the increasing prevalence of heavy drinking and obesity, cirrhosis is among the leading causes of 
death, especially in the middle-aged (Heron 2010). Hepatic status is often mirrored by measuring 
the  activities  of  liver  enzymes  from  serum.  It  appears,  however,  that  little  is  known  about  the  
effects of ethanol and adiposity in their earliest phase. Further understanding would also be 
important, since liver enzymes have been suggested to associate as well with cardiovascular 
diseases and type 2 diabetes (Fraser et al. 2009, Targher 2010).  
 
The aim of this study was to investigate the effects of rather low levels of alcohol drinking 
and excess body weight on the liver enzymes and other laboratory markers. These effects were 
studied both separately for each factor and in combination. The aim was also to clarify the 
mechanisms of pathology and to evaluate whether increased alcohol consumption and adiposity 
have influenced the concept of what is considered to be normal for various laboratory analytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Per capita alcohol consumption and mean conscript weight over time (Finnish Defence 
Forces 2010, THL 2010). (Mean conscript height remained unchanged.) 
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2. Review of the literature 
2.1 Alcohol through history 
Alcohol is a product that has provided a variety of functions for people throughout history 
(Hanson 1995). While no one knows when beverage alcohol was first used, it was presumably 
the result of a fortuitous accident occurring at least tens of thousands of years ago. The discovery 
of late Stone Age beer jugs has established the fact that purposely fermented beverages existed at 
least as early as about 12,000 years ago, and it has been suggested that beer may have been used 
as a staple before humans learned to make bread. The levels of amino acids and vitamins in 
beverages increase during fermentation, which may explain the frequent lack of nutritional 
deficiencies in populations whose diets were generally poor. Alcoholic beverages have also long 
served as thirst quenchers, since water supplies in the past have often been either unhealthy or 
questionable at best. Experience had shown that alcoholic drinks were safer than plain water, 
which was usually taken from sources used to dispose of sewage and garbage. Other antiseptic 
and medicinal uses of alcohol were widespread as well and related was the interest of 
contemporary health professionals in the discovery of distillation. In medieval Europe, distilled 
alcohol was hoped for as a cure to ailments. While this obviously was an illusion, alcohol was, 
however, important for example during the horrors of the Black Death by providing relief from 
sickness through relaxation, by improving mood and by easing of pain. From the earliest times to 
the  present,  alcohol  has  also  played  an  important  role  in  religion  and  worship,  as  a  social  
lubricant and as an enhancer of eating pleasure. 
 
Today,  many  of  the  historical  functions  of  alcohol  have  become  obsolete  and  its  harmful  
effects often exceed the benefits. It has been known for centuries that excess alcohol 
consumption is somehow associated with increased illness and death. In the 1920s, studies of the 
death rates among the various types of drinkers found that heavy drinkers had higher rates of 
overall mortality and of mortality from cirrhosis than did lighter drinkers or abstainers (Pearl 
1926). Since then, the diseases linked to alcohol consumption have continued to grow and 
become an enormous burden to modern society. 
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2.2 Effects of ethanol on health 
2.2.1 Alcohol-related general health problems  
Almost all tissues in the body are affected by ethanol and it is closely related to more than 60 
medical conditions (Rehm et al. 2003). The adverse health effects of excessive or even moderate 
ethanol consumption include both physiological and mental problems. There are also distinct 
differences in the effects resulting from the different patterns of ethanol intake, with the chronic 
pattern producing a different array of health hazards than acute (binge) drinking. Acute ethanol 
intake is typically presented in injuries and poisonings, and in increased suicide and violence 
rates. For example, the studies of trauma patients have shown that alcohol is involved in about 
two-thirds of their head injuries, and that the relative risk starts to increase sharply above a blood 
alcohol level of 1.5‰ (Savola et al. 2005). 
 
Alcohol metabolism occurs mainly in the liver, which is also therefore a major target for 
chronic ethanol toxicity. As a consequence, only a few days' consumption of excess alcohol may 
cause fatty changes in the liver (Lieber 1995), although these are usually reversible (Diehl 1998, 
Younossi 1998, Mann et al. 2003). Nonetheless, with continued drinking, the accumulation of fat 
is a common finding (Younossi 1998, Bellentani et al. 2000) and an early sign of alcoholic liver 
disease (ALD), which can further progress to alcoholic hepatitis and fibrosis. An often life-
threatening condition of cirrhosis develops in about 10–15% of all alcoholics (Mann et al. 2003). 
In addition to the liver problems, adverse health effects related to chronic alcohol intake also 
include pancreatitis, hypertension, arrhythmias, cardiomyopathy, gastrointestinal problems, 
increased susceptibility to infections, skin problems, hormonal disturbances, gout, several types 
of cancers, neurologic symptoms and psychiatric disorders (MacGregor and Louria 1997, Rehm 
et al. 2003, Choi et al. 2004, Bhole et al. 2010, Qureshi et al. 2010). 
 
One of the most devastating manifestations of ethanol-related harm is fetal alcohol spectrum 
disorders (FASD), which are developmental defects caused by prenatal alcohol exposure (Autti-
Rämö et al. 2008). FASD vary in severity, ranging from isolated dysmorphosis to profound 
abnormalities in craniofacial features, growth and intellectual functioning. It is not currently 
known what amount of ethanol, if any, can safely be consumed during pregnancy. Studies 
suggest that even very low levels of alcohol can lead to adverse consequences at a group level 
(Sood et al. 2001, Sayal et al. 2007, van Faassen and Niemelä 2011). The consensus is that the 
risk of damage to the fetus increases significantly after about 1–2 drinks per day or with 
recurrent consumption of more than 5 drinks on a single occasion, the high occasional blood 
alcohol levels further possessing a greater risk than lower continuous consumption (Autti-Rämö 
et al. 2008). In Finland approximately 3,000 pregnancies yearly are carried by substance-
dependent mothers, and at least 550 newborns per year suffer from FASD (Autti-Rämö et al. 
2008). 
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2.2.2 Suggested positive effects of alcohol 
During the past few decades, the possibility that small amounts of alcoholic beverages could 
promote longevity has been discussed repeatedly. A recent meta-analysis comprising 34 follow-
up studies and more than a million subjects showed the lowest total mortality to be at 
approximately half a drink daily (corresponding to 6 g of alcohol), but up to 2–4 drinks daily in 
men and 1–2 drinks daily in women still conferred benefit (Di Castelnuovo et al. 2006). The 
typical dose-response curve between alcohol and total mortality is J-shaped: compared to 
abstainers, the risk declines with a low level of alcohol consumption, while excess consumption 
is associated with increased risks. 
 
The  benefits  of  alcohol  drinking  are  thought  to  be  mainly  due  to  the  prevention  of  
cardiovascular diseases. Protection can result from increased or modified high-density 
lipoprotein (HDL) cholesterol, improved insulin signalling, from favorable changes in 
hemostatic profiles, and from reduced inflammation (Liisanantti et al. 2004, Bau et al. 2007, 
Mäkelä et al. 2008, Liisanantti and Savolainen 2009). Positive effects have been shown to derive 
from both ethanol itself, as well as from other components in alcoholic beverages. Especially red 
wine has often been mentioned. Interestingly, some studies have suggested acutely improved 
coronary  blood  flow  from  red  wine  but  not  from  de-alcoholized  red  wine  or  from  cognac  
(Kiviniemi et al. 2007, Kiviniemi et al. 2008). Thus far no uniform evidence, however, exists as 
to the type of beverage which produces the most benefit.  
 
It remains controversial as to whether patients with a high risk of cardiovascular disease 
should  be  advised  to  drink  small  amounts  of  alcohol,  as  the  benefits  appear  to  be  a  matter  of  
context. For instance, HDL-cholesterol concentration continues to rise beyond moderate drinking 
and can, in fact, sometimes be used as a marker of recent excessive alcohol intake (Szegedi et al. 
2000). The benefits are also disproportionate across ages: a direct dose-response relation 
between alcohol consumption and death has been reported in men aged 16–34 and in women 
aged 16–44, and a U-shaped relation starting at age 35–44 in men and at age 55–65 in women 
(White et al. 2002). Another important issue with respect to the health effects of ethanol has been 
raised by the extraordinary fluctuations in life expectancy in parts of the former Soviet Union 
since the mid-1980s (Leon et al. 1997, Shkolnikov et al. 2001). There the large changes in 
alcohol consumption and deaths from acute alcohol poisonings and coronary heart disease occur 
in parallel. It has been argued that binge drinking, a pattern of consumption common in Russia, 
may be leading to sudden cardiac deaths that are not classic deaths from coronary heart disease 
(McKee and Britton 1998, McKee et al. 2001). In Finland, acute drinking of intoxicating 
amounts has been shown to associate with an increased risk of cardiogenic brain embolism in 
subjects who have an existing source of thrombus (Hillbom et al. 1999).  
 
Currently, the data are not yet sufficient to encourage those who do not drink alcohol to start, 
especially as some individuals always will find it difficult to drink moderately, and because the 
risks among teenagers and young adults outweigh any benefits that may accrue later in life 
(National Institute on Alcohol Abuse and Alcoholism 2000, Bau et al. 2007). Moreover, the 
same beneficial effects could in most cases probably be achieved with regular exercise and 
proper diet, without the risks related to alcohol consumption. 
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2.2.3 Gender-dependent consequences of alcohol intake 
The maximum amount of ethanol recommended for women is about half of that for men and 
likewise with heavier consumption, the health hazards appear at lower doses in women than in 
men (White et al. 2002). Several reasons have been postulated for that, which are also likely to 
exist in combinations: 1) Women are usually smaller in size and therefore experience higher 
blood  ethanol  concentrations  than  men  after  consuming  the  same  amount  of  ethanol;  2)  Even  
with the same amount ingested per kg of body weight, the concentrations are higher in women 
because of their having less body water to dilute the ethanol; 3) In addition, the rate of alcohol 
metabolism in the stomach (first-pass metabolism) is lower and more ethanol enters the 
circulation (Schenker 1997); 4) In premenopausal women, the potential beneficial effects of 
drinking are weakened by their inherently low risk of cardiovascular diseases; 5) Women are 
also more susceptible to liver damage, possibly relating to the actions of sex hormones (Sato et 
al. 2001); 6) And finally, the risk of breast cancer is increased by about 10% for each additional 
daily drink (Longnecker 1994, Ellison et al. 2001). 
2.2.4 Other aspects determining the individual susceptibility to alcohol-related 
health problems 
In addition to the previously discussed effects of gender, and drinking pattern (2.2.2), various 
other factors also influence an individual's susceptibility to alcohol-related adverse health effects. 
Of these, perhaps the most commonly known difference in the effects of alcohol is caused by the 
genes encoding alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) enzymes. 
Certain gene variants encode enzyme forms that metabolize ethanol faster than the others or are 
unable to process acetaldehyde, the first metabolite of ethanol. The concomitant build-up of 
acetaldehyde results in the Oriental flushing syndrome, which is characterized by facial flushing, 
palpitations, nausea, headache, and other symptoms and which also associates with cancers of 
the head and neck (Yokoyama and Omori 2003, Brennan et al. 2004). As indicated by its name, 
the related gene variants are frequently observed in Asians; in Caucasians they are rare. 
However, some Caucasians also experience alcohol-related flushing, although it is of much 
shorter duration and intensity, and does not appear to dictate the amount of ethanol consumed. 
This flush has been suggested to be due to inherited low cytosolic ALDH activity (Ward et al. 
1994, Ward et al. 1998), whereas the mutations in Asians affect the enzymes in the 
mitochondria. 
 
There are also genetic differences in one's susceptibility to liver damage, although in our 
population, environmental factors appear to predominate in varying the risk. According to a 2006 
review, the only independently replicated observation of an association between genes and ALD 
in Caucasians has been with the tumor necrosis factor-Į (TNF-Į) -238 polymorphism (Day 
2006). Among environmental factors, the universal evidence on the role of obesity and smoking 
is solid (Klatsky et al. 2006). In addition, coexisting hepatitis B or C infections and the use of 
drugs may also influence the individual course of alcohol-related liver damage. On the other 
hand, coffee consumption has been shown to protect against liver dysfunction (Klatsky et al. 
2006). Protective mechanisms have been suggested both at the cellular level through both anti-
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inflammatory and anti-fibrotic effects, and at the epigenetic level through the reversal of ethanol-
related histone acetylations in pro-inflammatory genes and the consequential changes in the 
chromatin conformation that have facilitated transcription (Shukla and Aroor 2006, Kendrick 
and Day 2007, Kendrick et al. 2010). 
2.3 Assessment of ethanol consumption 
2.3.1 Definition of drinking patterns 
The risks associated with ethanol consumption are influenced both by the amount and the way of 
drinking. Based on these two, the different drinking behaviors can be classified into five basic 
patterns as follows (Saunders and Lee 2000, Saunders 2006): 
 
1)  Alcohol abstainers  
2)   Moderate drinkers, whose drinking does not generally cause problems either for the drinker 
  or for society, and who generally avoid becoming intoxicated 
3) Hazardous drinkers, who consume large amounts alcohol on certain occasions (binging), 
 or  relatively  large  amounts  frequently,  but  who  show  no  obvious  immediate  disorders.  
 Alcohol-related problems, nevertheless, are likely to emerge in the future, if the same 
 drinking behavior is continued 
4)  Harmful drinkers, who have physical or mental problems due to their drinking, although 
  they do not fulfil the criteria for alcohol dependence 
5)   Alcoholics, who meet the criteria for alcohol dependence including alcohol craving and the 
  presence of tolerance and withdrawal symptoms. 
 
In practice, the differentiation between moderate and excessive alcohol consumption is 
difficult  and,  consequently,  the  thresholds  for  defining  the  different  patterns  also  often  exhibit  
variation, depending on the source and country. In Finland, drinking is considered to be 
excessive in males consuming 24 standard drinks or more per week on average, or 7 standard 
drinks or more per occasion weekly (Sillanaukee et al. 1992). In females, the corresponding 
limits are 16 drinks or more and 5 drinks or more, respectively. A Finnish standard drink is 12 g 
of pure alcohol, which is the amount contained in each of 33 cl regular beer, 12 cl wine and 4 cl 
spirits. Compared to many other countries, our national guidelines can be considered to tolerate 
quite heavy consumption. In the United Kingdom, for instance, the limits are set at 168 g (about 
14 Finnish drinks) for men and 112 g (about 9 Finnish drinks) for women weekly, including 2 or 
3 days without any alcohol (Royal College of Physicians 1987). In the United States, the 
recommended criteria for drinking that associates with an increased risk of alcohol-related 
problems is more than 4 drinks a day, or more than 14 per week for men, and more than 3 drinks 
a day, or more than 7 per week for women with the assumption of 14 g of ethanol in one drink 
(National Institute on Alcohol Abuse and Alcoholism 2005). Probably the most referenced 
guideline is that of the American Heart Association, which stipulates that alcohol consumption 
should be limited to no more than 2 drinks per day for men and 1 drink per day for women, and 
that ideally, consumption occurs with meals (Lichtenstein et al. 2006). In addition to describing 
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the current drinking pattern with the help of pre-defined criteria, the introduction of a category of 
former drinkers is often important in research settings to avoid bias due to individuals who 
stopped drinking because of health problems (Di Castelnuovo et al. 2006). 
2.3.2 Self-reporting of drinking habits 
Self-reporting is used in health care settings to detect adverse drinking habits, and is used in 
research to quantify the amount of ethanol consumed. The method itself is considered to be 
powerful, but its reliability decreases if the patient has memory problems, difficulties in 
understanding questions, problems in performing calculations to quantify drinking or has a 
tendency for intentional dissimulation. In addition, unintentional misestimating may also bias the 
results. One study on college students revealed a clear overestimation of the amount of fluid that 
should be poured to create a standard drink (White et al. 2003). The volume of one serving has 
also increased in recent years in both restaurants and grocery stores, now more often deviating 
from a standard drink and thus possibly increasing underestimation.  
 
The  Alcohol  Use  Disorders  Identification  Test  (AUDIT)  is  a  specific  questionnaire  for  
screening alcohol abuse (Saunders et al. 1993). It consists of a total of 10 questions, which focus 
mainly on the level and frequency of consumption and the adverse consequences of drinking. 
AUDIT is considered as the most sensitive among the current questionnaires to detect hazardous 
and harmful drinking (Seppä et al. 1995, MacKenzie et al. 1996, Reid et al. 1999) and its shorter 
versions have also been found to be effective and can be chosen for use in busy medical offices 
and emergency rooms (Tuunanen et al. 2007, Aalto et al. 2009). In case of a positive screen test, 
brief intervention of at least 5–10 minutes should be delivered to let the patient know the risks 
that follow from such drinking, and to motivate and give tools to reduce consumption (Kaner et 
al. 2007, McQueen et al. 2009). In addition to AUDIT, the other well-known questionnaires are 
the four-question CAGE (acronym of the key words in its questions: cut down, annoyed, guilty, 
eye-opener) (Ewing 1984) and the Michigan Alcoholism Screening Test (MAST) (Selzer 1971), 
which is the most extensive of these with 25 questions directed at the recognition of drinking 
problems, help-seeking behavior and alcohol-related disabilities.  
 
A  commonly  used  means  of  quantifying  the  amount  of  ethanol  consumed  is  to  use  the  
timeline follow-back (TLFB) method (Sobell and Sobell 1992), or alternatively to simply ask 
about the average, e.g., weekly consumption in the preceding, e.g., 12 months. In the TLFB 
approach, the patient is asked his or her specific recollections of drinks and volumes during a 
given time period, which contrary to asking an average, also gives an opportunity to assess the 
individual's patterns of drinking.  
2.3.3 Markers of ethanol consumption 
Self-reporting or clinical observation are often limited in means of detecting excessive drinking 
and therefore various laboratory tests are used for more objective assessments (Hannuksela et al. 
2007).  Some  of  the  tests  assess  alcohol  consumption  directly  by  measuring  ethanol  or  other  
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specific compounds in the body fluids, and these are discussed below. An assessment can also be 
made indirectly through the evaluation of liver function, but since hepatic health is affected by 
various other factors than ethanol as well, such markers will be covered later in section 2.7.5 
(2.7.5.1 Ȗ-Glutamyltransferase (GGT), 2.7.5.2 Aminotransferases (ALT, AST)). 
2.3.3.1 Ethanol concentration in body fluids 
The ethanol concentration of blood, breath, or urine can be used to assess recent alcohol 
consumption, and when combined with clinical observations, they may also provide information 
on long-term drinking habits (Niemelä 2007). According to the National Council on Alcoholism 
(1972), concentration of blood alcohol exceeding 1.5‰ (150 mg/dl, 33 mmol/l) without obvious 
evidence of intoxication, 3‰ (300 mg/dl, 65 mmol/l) on any given occasion, or 1‰ (100 mg/dl, 
22 mmol/l) when occurring in routine examination, is suggestive of alcoholism. Already 
concentration less than 1‰ in routine examination may be interpreted as being risky alcohol 
behavior (Käypä hoito 2010). In trauma patients, the blood alcohol concentration at the time of 
admission has been reported to be the best indicator of hazardous drinking practises and alcohol 
dependence (Ryb et al. 1999, Savola et al. 2004). 
2.3.3.2 Carbohydrate-deficient transferrin (CDT) 
Carbohydrate-deficient transferrin (CDT) is defined as an aberrant glycoform of transferrin, 
characterized by a reduced number of carbohydrate (sialic acid) moieties (Stibler and Kjellin 
1976, Stibler 1991). Whereas the predominant isoform of transferrin in healthy individuals is 
tetrasialotransferrin, with four sialic acid moieties, excessive drinking has been shown to 
increase asialo- and disialotransferrin, with none and two sialic acids, respectively (Mårtensson 
et al. 1997, Helander et al. 2001). To account for the variation in total transferrin, CDT is further 
presented as a percentage of all isoforms (Sorvajärvi et al. 1996).  
 
CDT is currently the most widely used marker for chronic excessive alcohol consumption. 
There is thus far no uniform opinion, however, on the amount and pattern of drinking needed to 
increase CDT. It is considered that rather large amounts, at least 50–80 g of ethanol daily for at 
least a week, may have to be consumed (Stibler 1991) and the consensus has become that CDT is 
not suitable for the screening of alcohol abuse in the general population, but rather should be 
measured when excess consumption is suspected. The sensitivities of CDT to detect alcohol 
abuse have mostly varied from 30% to 90% in different studies, depending on the population 
(Bortolotti et al. 2006). Lower sensitivities have been detected in women than in men, in 
overweight than in normal weight individuals, and in non-smokers than in smokers (Whitfield et 
al. 2008). Especially high sensitivities have been shown in relapsed alcohol abusers in whom 
CDT may increase at relatively lower levels of consumption, possibly due to sensitization 
(Walter et al. 2001). Subsequently, one special application in the field is to monitor CDT in the 
drunk drivers applying for licence regranting (normalization in about two weeks (Stibler 1991)). 
In addition to population differences, the comparison between different studies concerning the 
sensitivity of CDT has also been hampered by the lack of standardization, which nevertheless is 
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now in progress. While different methods at present may measure different isoforms, the  
recommendations of the working group have defined disialotransferrin as the primary target 
molecule for CDT measurement and as the single analyte on which standardization is to be based 
(Jeppsson et al. 2007). Recently, the successful establishment of a network of reference 
laboratories and candidate reference material was also reported (Oberrauch et al. 2008, Helander 
et al. 2010). In addition, a calibration trial among laboratories covering the current routine assays 
was presented, showing a marked reduction in the total coefficient of variation and practical 
functionality and accompanied by a conclusion that an appropriate reference system for CDT 
may soon become a reality (Helander et al. 2010).  
 
The advantage of CDT as an analyte is its high specificity, in that it is not influenced by the 
presence of liver disease unless very severe (Stibler 1991, DiMartini et al. 2001, Berlakovich et 
al. 2004). A limited number of false results may follow from conditions such as congenital 
disorders of glycosylation or from genetic transferrin variants (Stibler 1991). These problems are 
especially related to immunological methods, except the latest launch N Latex CDT from Dade 
Behring (A Siemens Company), which should be insensitive to genetic transferrin variants 
(Delanghe et al. 2007). The other available methods, high performance liquid chromatography 
(HPLC) and capillary electrophoresis (CE), are generally more laborious and time-consuming 
procedures, but they are beneficial in visibly documenting and the concomitant possibility for 
detecting analytically divergent transferrin patterns. 
2.3.3.3 Mean corpuscular volume (MCV) 
Increased mean corpuscular volume (MCV, red blood cell size), or macrocytosis, is typical of 
people with chronic excessive ethanol intake (Niemelä 2007, Käypä hoito 2010). In non-anaemic 
men, increased MCV is nearly always due to a problem drinking. In women, about one-third of 
non-anaemic cases are related to alcohol. MCV may also increase due to deficiencies of vitamin 
B12 and folic acid, hypothyroidism, reticulocytosis, liver diseases, blood diseases and smoking. 
In  another  third  of  macrocytic  women,  the  etiology  nevertheless  remains  unsolved.  The  
sensitivity of MCV in detecting harmful drinking and alcohol dependence is generally rather 
high, but less than that of CDT or GGT in detecting hazardous drinking. Some studies have, 
however, suggested MCV to be the best of the traditional markers for assessing female patients 
(Sillanaukee et al. 1998, Mundle et al. 2000). 
 
The normalization time of MCV is longer than that of other commonly employed markers, 
lasting 2–4 months. Such a slow response to abstinence places limitations on its use for the short-
term monitoring of drinking cessation, but offers a possibility for supervising longer periods 
(Morgan et al. 1981, Mundle et al. 1999). 
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2.3.3.4 Research markers not yet established in clinical routine 
Ethyl glucuronide (EtG) and ethyl sulphate (EtS) 
 
Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are promising new markers for ethanol 
consumption (Schmitt et al. 1995, Helander and Beck 2004, Høiseth et al. 2008). They are 
formed by the enzymatic conjugations of ethanol with glucuronic acid and sulfate, respectively, 
and remain detectable much longer than the parent compound. After ethanol has been eliminated 
from the body, EtG and EtS are measurable in the urine up to about 5 days, depending on the 
initial alcohol dosage but also showing great inter-individual variation (Helander et al. 2009a, 
Høiseth et al. 2009). In addition, small amounts may be detected after unintentional ethanol 
exposure (ethanol in mouth wash or hand sanitizer, endogenous ethanol from digestive tract 
bacteria) or due to the ingestion of the marker itself (in non-alcoholic wine) (Politi et al. 2005, 
Costantino et al. 2006, Rosano and Lin 2008, Høiseth et al. 2010). Recently, the first commercial 
EtG assay was launched (DRI Ethyl Glucuronide Enzyme Immunoassay (DRI-EtG EIA), 
Microgenics Corp.) (Böttcher et al. 2008, Arndt et al. 2009), which now also makes this marker 
available to facilities other than research laboratories. The drawback of EtG is, however, that 
both false-positive and -negative results may follow from the microbial contamination of 
specimens (Helander and Dahl 2005, Helander et al. 2007, Baranowski et al. 2008, Thierauf et 
al. 2008, Helander et al. 2009b). EtS has thus far proved to be reliable in all but one study (Halter 
et al. 2009), in which degradation was observed after days of storage under conditions 
resembling post-mortem putrefaction, and it has been suggested that EtS should possibly replace 
EtG in the future (Helander et al. 2007). 
 
Phosphatidylethanol (PEth) 
 
Phosphatidylethanol (PEth) is an ethanol-phospholipid adduct that is formed only in the presence 
of ethanol via the action of phospholipase D, at the expense of the natural product phosphatidic 
acid (Yang et al. 1967). PEth has been shown to be a sensitive (94.5–100%) and specific (100%) 
marker of the excess ethanol consumption in alcoholics with a detection window of up to 3–4 
weeks after the person's last drinking (Wurst et al. 2004, Hartmann et al. 2007, Wurst et al. 
2010). The threshold of total ethanol intake that yields detectable PEth has been considered to 
around 1,000 g, with a mean daily intake of about 50 g, whereas a 50 g dose on a single day has 
not been detected (Varga et al. 1998). However, recent advances in methodology suggest that 
with liquid chromatography-mass spectrometry analysis (LC-MS), instead of previous HPLC, it 
could be possible to detect low frequency or even single heavy drinking as well (Gnann et al. 
2009). LC-MS can also identify individual PEth species, which could allow for its 
standardization and use as a legally defendable confirmatory analysis (Helander and Zheng 
2009). In addition, the successful production of specific monoclonal antibodies also show 
promise for having an assay for total PEth available later for common expertise and for 
inexpensive laboratory equipment (Nissinen et al. 2008). The special characteristic of PEth that 
needs consideration, both in research and in routine, is its unsuitability for storage at room 
temperature and at í20 °C due to the risk of a false-positive result from the post-collection 
synthesis in the presence of ethanol; the samples may be stored at +4 °C up to 5 days and further 
at í80 °C (Aradóttir et al. 2004, Helander and Zheng 2009). 
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Fatty acid ethyl esters (FAEE) 
 
Fatty acid ethyl esters (FAEE) are non-oxidative metabolites of esterification of ethanol with 
fatty acids. In serum, the levels of FAEE remain elevated for up to 12–24 hours after the 
cessation of drinking (Doyle et al. 1996, Bisaga et al. 2005). In addition, a specific FAEE species 
– ethyl oleate – has been suggested as being higher in chronic alcoholics than in episodic 
drinkers (Soderberg et al. 2003). FAEE may also serve as long-term markers of ethanol intake 
when assessed, for example, from hair, in which concentrations have been shown to be different 
between alcoholics, moderate drinkers and abstainers (Auwärter et al. 2001, Yegles et al. 2004). 
Some FAEE may be found in the hair of strict abstainers as well, but a concentration above        
1 ng/ml can be taken as strong evidence of excessive drinking behavior. The level of elevation 
with heavy consumption, however, does not seem to quantitatively correlate with self-reported 
consumption. Rare false positive cases may result from contamination with ethanol-containing 
hair care products so that in doubtful cases, pubic hair should be analyzed for comparison 
(Hartwig  et  al.  2003).  A  promising  application  of  FAEE  is  the  assessment  of  FASD  from  
neonatal hair, which begins to grow around six to seven months of fetal life and is collectable 
until shedding around three months after birth (Caprara et al. 2006). In general, the sample 
processing and methods for FAEE analysis are labor- and time-intensive, including gas 
chromatography-mass spectrometry, and may prevent its routine use in clinical laboratories. 
 
Marker combinations: GGT-CDT 
 
The new combinations of old markers have also showed interesting possibilities in the recent 
literature, especially the mathematical formulation of GGT and CDT. The rationale for 
combining these two is that they frequently increase in different individuals and may represent 
different types of ethanol-induced pathophysiological processes (Löf et al. 1994, Helander et al. 
1996). The attempt is thus to gain the benefits of two diagnostic entities. Moreover, since both 
markers belong to the set of routine assays, their combination marker would be cost-effective 
and easy to manage in hospital laboratories. Conventionally, GGT and CDT have been combined 
by seeing whether either is elevated, but with this approach, the improved sensitivity is often 
accompanied by a loss of specificity (Salaspuro 1999, Anton et al. 2001, Schwan et al. 2004). 
The  equation  0.8  ×  ln(GGT)  +  1.3  ×  ln(CDT),  using  absolute  CDT  concentrations,  was  first  
introduced by Sillanaukee and Olsson (2001) and Sillanaukee et al. (2000), and later improved 
by Anttila and co-workers (2003), who replaced the absolute CDT concentrations with a CDT 
percentage of total transferrin. With these combinations, decreased specificity appears no longer 
to be an issue, while the sensitivity in most studies has exceeded that of the traditional markers 
(Sillanaukee et al. 2000a, Chen et al. 2003, Berner et al. 2006, Hietala et al. 2006, Bianchi et al. 
2010). In clinical work, it could make sense to interpret the results of both the combination 
marker and the single CDT to reach objective conclusions on a patient's alcohol consumption. 
Until the implementation of CDT standardization, the values of these measures may nevertheless 
differ between laboratories (Helander et al. 2010).  
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2.4 Obesity: past and present 
Reviewing the history of obesity reveals that it is an age-old condition.  The first sculptural 
representations of the human body about 20,000–35,000 years ago depict obese females (Conard 
2009). The sculptures are collectively described as "Venus" figurines in reference to the Roman 
goddess of beauty, since the prehistorians of the early 20th century assumed they represented an 
ancient symbol of wealth and fertility. 
 
In the course of time, the perception of obesity has varied. Once symbolizing fertility, ancient 
Egyptians  considered  obesity  to  be  a  disease  and  depicted  their  enemies  as  obese  individuals.  
The Aztecs believed that obesity was supernatural, but rather than a blessing, it was an affliction 
of the gods. In cultures struggling with food scarcity, however, obesity has been viewed if not as 
ideal beauty, at least as a sign of security and welfare. For example, obesity was common among 
high  officials  in  Europe  in  the  Middle  Ages  and  the  Renaissance.  In  fact,  even  today,  female  
fatness is viewed as a sign of social status and is a cultural symbol of beauty, prosperity and 
fertility in some areas of Africa (Mokhtar et al. 2001). 
 
The unique feature of the last century is the deviation of the concepts of ideal beauty and 
healthy body weight in Western society. The weight that is viewed as an ideal has become lower 
since the 1920s. This is illustrated by the fact that the average height of the Miss America 
pageant winners increased by 2% from 1922 to 1999, while their average weight decreased by 
12% (Rubinstein and Caballero 2000). On the other hand, people's views concerning healthy 
weight have moved in the opposite direction. In Britain, the weight at which people considered 
themselves to be overweight was significantly higher in 2007 than in 1999 (Johnson et al. 2008). 
This change is believed to be due to the increasing rates of adiposity, leading to an increased 
acceptance of extra body fat as being normal. With all the gathering of information on the 
dangers of obesity, this adjustment is considered alarming by many. 
2.5 Obesity as a health problem 
Obesity is a medical condition in which excess body fat has accumulated to the extent that health 
may be impaired (World Health Organization 2000). It is considered a chronic disease in its own 
(Burton and Foster 1985), in addition to which it further increases the risk of various other 
disorders, either directly or indirectly, through a shared cause of, for instance, poor diet or 
sedentary lifestyle. The most common co-morbidities include type 2 diabetes, hypertension, the 
metabolic syndrome, coronary heart disease, cerebral infarction and hemorrhage, sleep apnea, 
gout, gallbladder disease, non-alcoholic fatty liver disease (NAFLD), osteoarthritis, asthma, and 
at least cancers of the breast, cervix, large intestine and kidney (Käypä hoito 2006). Moreover, 
excess body weight may also have adverse effects on mental health and it may decrease fertility. 
In general, the higher the degree of obesity and the earlier its onset, the higher the risks of health 
problems. In a follow-up study conducted between 1948 and 1990, obesity at age 40 was 
estimated to reduce life expectancy by on average six to seven years (Peeters et al. 2003). 
Similar figures were also suggested in a recently published analysis of 57 follow-up studies, 
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which estimated that a body mass index (BMI) of 30–35 kg/m2 was associated with a two- to a 
four-year reduction in life expectancy, while a BMI of 40–45 kg/m2 had shortened life by eight 
to ten years (Prospective Studies Collaboration 2009).  
2.6 Assessment of excess body weight 
2.6.1 Body mass index (BMI) 
The most commonly used method for assessing obesity is to calculate the body mass index 
(BMI), which is defined as weight in kilograms divided by the square of height (kg/m2) 
(Eknoyan 2008). According to the recommendations by the World Health Organization (2000), 
BMI <18.50 kg/m2 denotes underweight, BMI 18.50–24.99 kg/m2 normal weight, BMI 25.00–
29.99 kg/m2 overweight, and BMI 30.00 kg/m2 obesity, so that the risk of co-morbidities 
usually is low with underweight (but the risk of other clinical problems is increased), average 
with normal weight, increased with overweight, and moderate to very severe in obesity, 
depending on its degree. These guidelines fit well with the white population and are considered 
to be the international classification; however, for some ethnicities, the risks are already 
substantial at a lower BMI than 25 kg/m2. In Asian and Pacific populations, a specific BMI 
reflects a higher percentage of body fat than the same BMI in, for example, Europeans, and 
therefore additional trigger points for public health actions for these have been recommended at 
23 kg/m2 (BMI 23.00–27.49 kg/m2, increased risk) and at 27.5 kg/m2 (BMI 27.50 kg/m2 or 
higher, high risk) (World Health Organization Expert Consultation 2004).  
2.6.2 Waist circumference 
Another tool for detecting obesity, and especially the related risks, is waist circumference. It is 
widely accepted that central obesity is more detrimental than peripheral obesity, and thus waist 
circumference is often a better predictor of diseases than BMI. Accordingly, waist circumference 
belongs to the definition of the metabolic syndrome, which is known as a cluster of risk factors 
for cardiovascular disease and type 2 diabetes (Eckel et al. 2005). The other risk factors include 
raised blood pressure, triglycerides and fasting glucose, and lowered HDL-cholesterol. There 
have, however, been discrepancies between the different guidelines (Adult Treatment Panel III 
2002, Alberti et al. 2005, Grundy et al. 2005) as to whether or not an increased waist 
circumference should always be present for diagnosis and how to set its thresholds. In an effort 
to unify the criteria, several major organizations lately created a joint interim statement (Alberti 
et al. 2009), suggesting that waist measurement would continue to be a useful preliminary 
screening tool, but should not be an obligatory component of the metabolic syndrome. Instead, a 
total of any three risk factors must be met. Furthermore, the cut-off points for elevated waist 
circumference should be population- and country-specific, but at least at this time, it would be up 
to local decision-making groups to choose between thresholds at which risk starts to increase 
94/80 cm for white men/women of European origin), or at which it already has substantially 
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increased (102/88 cm similarly). In general, the metabolic syndrome is estimated to double the 
risk of developing cardiovascular disease over the next five to ten years, while the risk over the 
lifetime undoubtedly is even more increased (Alberti et al. 2009). The risk of type 2 diabetes is 
approximated to become fivefold. 
2.7 Alcohol, obesity, and the liver 
2.7.1  Main features of alcoholic liver disease (ALD) 
Alcoholic liver disease (ALD) covers a wide spectrum of morphological abnormalities, ranging 
from fatty liver to alcoholic hepatitis, fibrosis and cirrhosis. These injuries usually develop 
sequentially, but may then exist in combinations (Diehl 1998). The most important factor for 
both the short-term and long-term survival of patients with ALD is abstinence from alcohol, 
although  the  disease  may  progress  despite  complete  sobriety  as  well  (Parés  et  al.  1986,  Diehl  
1998). 
 
Alcoholic fatty liver (steatosis) is the earliest and most common histological consequence of 
alcohol  abuse.  It  may  appear  even  after  a  few  days  of  excessive  ethanol  consumption  (Lieber  
1995), and is usually fully reversible (Diehl 1998, Younossi 1998, Mann et al. 2003). This 
condition may be due to several mechanisms (Donohue 2007). Traditionally, it was considered to 
result from an altered redox state generated by ethanol metabolism, providing more substrate 
availability for lipogenesis and inhibiting mitochondrial fatty acid oxidation. Later discoveries 
have also characterized ethanol- and acetaldehyde-related changes in cell signalling processes 
and transcription factor activities that eventually alter the expression of genes involved in lipid 
biosynthesis, and in fatty acid transport and oxidation. Fatty liver is often accompanied by 
hepatomegaly, but typically occurs without any clinical symptoms (Diehl 1998, Mann et al. 
2003). 
 
Alcoholic hepatitis, mostly presenting in the form of steatohepatitis, is a clinically severe 
condition characterized by fat accumulation, inflammation and liver cell death (necrosis) (Diehl 
1998). Patients with alcoholic hepatitis may be asymptomatic, only have an enlarged liver and 
perhaps some abdominal pain, or have a full-blown picture with tender hepatomegaly, jaundice, 
fever, malaise, anorexia, nausea and vomiting, liver failure and bleeding (Diehl 1998, Mann et 
al. 2003). 
 
Fibrosis is considered to be an early feature of ALD, elicited by chronic hepatic 
necroinflammation and eventually leading in some subjects to cirrhosis (Diehl 1998). Fibrosis is 
defined as a gradual deposition of excessive connective tissue (scarring), whereas cirrhosis is a 
condition involving the whole liver, in which replacement of normal parenchyma with 
broadening bands of collagen causes a loss of liver function. Cirrhosis is irreversible and the 
most serious form of ALD associating with high mortality and many serious symptoms 
(Younossi 1998, Heron 2010). 
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2.7.2  ALD and obesity 
Obesity potentiates the severity of alcohol-induced liver damage. Results of several population-
based studies raise the concern that both the prevalence and severity of alcohol-related liver 
disease may be rising in conjunction with the obesity epidemic, since obesity seems to increase 
all stages of ALD from fatty liver to cirrhosis (Naveau et al. 1997, Bellentani et al. 2000, 
Raynard  et  al.  2002).  Similarly,  obesity  is  also  a  risk  factor  in  the  liver  diseases  of  other  
etiologies, such as chronic hepatitis C (Nieminen et al. 2009). It is currently unclear whether the 
hepatotoxic consequences of obesity and ethanol ingestion are additive or synergistic (Diehl 
2004), although the most recent studies are supportive of synergism (interaction), i.e., the 
combined effects of obesity and alcohol would be greater than the simple additive effects of each 
factor separately (Hart et al. 2010, Liu et al. 2010). 
 
Several mechanisms have been postulated by which obesity could promote ALD. It has 
become apparent that adipose tissue is not an inert storage of excess fat, but in fact is a very 
active organ, which may contribute to the development and the severity of alcoholic liver disease 
by at least increasing insulin resistance and the production of cytokine TNF-Į, as well by 
producing angiotensin II, norepinephrine, neuropeptide Y, and leptin (summarized by Diehl 
2004). TNF-Į, for example, belongs to the proinflammatory cytokines and plays an important 
role in initiating the inflammatory cascade in alcoholic hepatitis. Moreover, TNF-Į is produced 
in significantly greater amounts by visceral fat than by subcutaneous fat, and ethanol may further 
increase the production by influencing fat distribution, i.e., by decreasing the subcutaneous fat 
and by increasing the visceral fat. Insulin resistance is also related especially to visceral fat and 
frequently causes steatosis. Given that the converse similarly is true, that the accumulation of fat 
in the liver causes insulin resistance, the combined effect of obesity and alcohol on steatosis 
could be of greater magnitude than that of a single component. Angiotensin II, norepinephrine, 
neuropeptide Y, and leptin in turn have been characterized as fibrogenic agents. For more 
detailed descriptions and references on all of these, see the above-mentioned article. Yet one 
other possible mechanism, oxidative stress, will also be discussed in 2.7.4.  
2.7.3  Non-alcoholic fatty liver disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) is characterized by a hepatic fat accumulation in the 
absence of significant ethanol consumption, viral infection, or other specific causes of liver 
pathology. Its prevalence has been increasing parallel with the increasing prevalence of obesity, 
diabetes and the other components of the metabolic syndrome, and subsequently NAFLD has 
become accepted as the hepatic manifestation of the metabolic syndrome (Marchesini et al. 
2001) and recognized as the most common chronic liver disease in the Western societies.  
 
Similarly to alcoholic liver disease, NAFLD includes a spectrum of clinicopathological 
entities ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), with the 
possibility of progression to cirrhosis (Matteoni et al. 1999). However, contrary to the alcoholic 
etiology, NASH is usually a silent disease with few or no symptoms (Ali  and Cusi 2009).  The 
occurrence of NAFLD has been estimated to be 20–30% in the general population and much 
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higher in the obese, being an almost universal finding in obese patients with type 2 diabetes 
(Neuschwander-Tetri and Caldwell 2003, Bellentani and Marino 2009). About at least 10% of 
the NAFLD-subjects have NASH, with the progression rate of approximately up to one-third to 
cirrhosis (Neuschwander-Tetri and Caldwell 2003). However, the most prevalent cause of death 
in those with NAFLD is due to cardiovascular diseases (Ong et al. 2008). To date no single 
intervention has been reliably effective for NAFLD and NASH, and the cornerstones of the 
current recommendations are the treatment of comorbid conditions associated with the metabolic 
syndrome and the reversal of predisposing factors (Lam and Younossi 2009). In relation to 
weight loss, it appears that physical activity may be of benefit even without a reduction in body 
weight (Caldwell and Lazo 2009). This can have great motivational importance for patients 
attempting lifestyle changes. 
 
Insulin resistance is considered to be important in the development of NAFLD (Almeda-
Valdés et al. 2009). Peripheral insulin resistance causes triglyceride lipolysis within the adipose 
depots and inhibits adipocyte uptake of fatty acids, both these increasing the delivery of fatty 
acids to the liver. The compensatory hyperinsulinemia in turn promotes hepatic de-novo 
lipogenesis and esterification of fatty acids into triglycerides, and decreases fatty acid oxidation. 
Hence obesity, which often leads to insulin resistance and particularly in such cases, presents a 
fatty challenge to the liver. 
  
It was long uncertain as to whether or not ALD and NAFLD are similar in their pathologies. 
However, that controversy has been considered as having been solved by the work of Xu and co-
workers in 2003, showing the fat-derived hormone adiponectin to be effective in alleviating both 
the alcohol-induced and obesity-induced liver abnormality in mice. The improvement was 
suggested in part due to a suppression of TNF-Į production and also an antagonism of its 
function, in that adiponectin and TNF-Į elicit many opposite functions, for example, TNF-Į 
being a causative factor of insulin resistance, whereas adiponectin increases insulin sensitivity. 
Similarly, TNF-Į is a proinflammatory cytokine, whereas adiponectin has direct anti-
inflammatory effects. Although the primary etiology of NAFLD and ALD is different, these liver 
diseases apparently share similarities in their progression. Interestingly, Wang and co-workers 
(2010) recently demonstrated that experimental NASH is aggravated already by moderate 
ethanol administration. 
2.7.4  Postulated mechanism: oxidative stress 
One of the most advocated mechanisms that could explain why alcohol and obesity, for example, 
potentiate each other in progression from fatty liver to steatohepatitis and fibrosis, is oxidative 
stress.  This  mechanism  is  called  "the  theory  of  two  hits",  and  the  editorial  by  Day  and  James  
(1998) introducing it has since become extensively cited in related research. Briefly, the first hit 
is the deposition of fat in the liver triggered by different factors, which renders the hepatocytes 
susceptible towards the second hit, the oxidative stress. 
 
The origins of the theory lie in the difficulties to develop animal models of severe alcoholic 
liver disease by administering simple ethanol. In other words, further manipulations are needed 
to produce necroinflammation and fibrosis (Lieber 1988). Similarly, many patients with non-
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alcoholic steatosis never progress in their disease. Although some degree of oxidative stress can 
be seen in the steatosis of most etiologies (Lettéron et al. 1996), it is believed that an alternative 
or extra source of oxidative stress is needed to escape the cellular defence systems and to 
progress from a fatty liver. For example, most reactive oxygen species generated in the livers of 
ethanol-fed rats are produced in microsomes through the cytochrome P450 enzyme system 
(Lieber 1997), and further induction of this system by polyunsaturated fatty acids aggravates 
liver injury (Nanji et al. 1994). In addition, iron can be used to increase the oxidative toxicity in 
experimental animals (Tsukamoto et al. 1995) (ferrous iron exacerbates oxidative stress by a 
Fenton chemistry reaction with hydrogen peroxide and superoxide to yield more potent oxidants 
(Halliwell and Gutteridge 1984, Aust et al. 1985)) and, indeed, hepatic iron overload is 
associated with the liver damage severity in alcoholics and possibly also in NAFLD (Ganne-
Carrié et al. 2000, Bonkovsky et al. 2003, Machado et al. 2009, Wallace and Subramaniam 
2009). Insulin resistance on the other hand has been suggested as being capable of playing the 
roles of both the first and the second hit, since it often leads to fatty liver, which further 
decreases insulin sensitivity (Day 2002). The connections between insulin resistance, 
steatohepatitis and oxidative stress have been supported by the observations that individuals with 
NASH are significantly more insulin resistant than those with a fatty liver alone and that 
oxidative damage is more pronounced in NASH than in simple steatosis (Dixon et al. 2001, 
Marchesini et al. 2001, Sanyal et al. 2001).  
 
In  conclusion,  the  theory  of  two  hits  postulates  that  in  the  presence  of  one  etiology  strong  
enough to induce fatty liver in a considered individual, the additional oxidative stress by the 
second etiology markedly increases the risk for progressive liver damage (Day and James 1998). 
However, to add to the complexity, it must be noted that liver damage may be aggravated 
without an indication of increased oxidative damage as well (Wang et al. 2010). It was also 
recently emphasized by Choi and Diehl (2008) that fat accumulation itself may not necessarily 
be  harmful  and  the  first  hit  that  sensitizes  the  liver  for  more  serious  damage,  as  is  often  
interpreted; rather, the authors showed that the inhibition of fat accumulation worsened the 
hepatic injury in an experimental model of progressive NAFLD, and concluded that the 
deposition of triglycerides was actually protective in these animals and simply a reflection of the 
ongoing burden and impending lipotoxicity by the free fatty acids.  
2.7.5 Related laboratory tests 
Advanced liver disease induces abnormalities in several laboratory markers (Rosman and Lieber 
1994). For example, the levels of serum albumin usually decrease due to a decreased synthetic 
capacity of the hepatic tissue as there are elongations in the prothrombin time (causing defective 
coagulation) as well. Impaired bilirubin removal and subsequent build-up may even be observed 
as  a  yellowish  colour  of  the  patient.  Both  in  the  advanced  and  earlier  stage  of  pathology,  the  
measurements of serum liver enzymes also serve as important diagnostic information. 
Analogously to the scope of the present design, these are discussed more below. Serum uric acid 
is not a liver marker per se, but is included owing to its role as a possible indicator of oxidative 
stress. 
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2.7.5.1 Ȗ-Glutamyltransferase (GGT) 
Serum Ȗ-glutamyltransferase (GGT) is an enzyme derived from the liver, the changes in its 
activity having been used to monitor excessive alcohol consumption for several decades. In fact, 
GGT has been the most commonly used laboratory marker of heavy drinking. Several studies 
have reported a positive correlation between the amount of ethanol ingested and serum GGT 
levels, but the sensitivity of GGT has varied greatly between populations, from 10 to 90%, being 
lower in samples from the general practice and in the young (Salaspuro 1999). In addition, GGT 
tends to have a relatively low specificity for alcohol consumption, because it may also elevate, 
e.g., due to diabetes, obesity, pancreatitis, hyperlipidemia, cardiac insufficiency, severe trauma, 
nephrotic  syndrome,  renal  rejection,  and  medication,  and  in  patients  with  other  than  alcoholic  
forms of liver diseases (Niemelä 2007). Although the factors affecting GGT are numerous and 
individual variability in the reactivity to the changes in the body may be great, it has been 
suggested that even moderate alcohol consumption for a few consecutive nights might increase 
the  activity  of  GGT  in  the  blood  for  some  days,  as  compared  to  the  individual  baseline  value  
(Freer and Statland 1977a, Freer and Statland 1977b, Nemesánszky et al. 1988). With heavier 
consumption, normalization may take up to about 4–5 weeks (Anton et al. 2002), and as patients 
with non-ethanol related liver abnormality usually do not show profound changes in their GGT 
in the short-term, e.g., one week (Pol et al. 1990), documentation of decreased activity can be 
helpful in the differential diagnosis in pointing toward alcohol etiology.  
 
Markedly increased GGT activities are usually considered to reflect tissue damage, especially 
if associated with abnormalities in other liver enzymes, but an increase may also be due to other 
reasons. Mild elevations of GGT can relate to its biological function to maintain the intracellular 
levels of glutathione and to metabolize glutathione conjugates (Zhang and Forman 2009). 
Glutathione is an important antioxidant, ant its removal causes loss of viability, for example, in 
the cytochrome P450 2E1 (CYP2E1) enzyme expressing cells (Wu and Cederbaum 2001). The 
key features of CYP2E1 are its leakage of free radicals and subsequent oxidative stress, and the 
fact that ethanol is among the substrates of CYP2E1, especially when the alcohol dehydrogenase 
pathway is saturated by heavy drinking (Lieber 1997). In general and by various ways, oxidative 
stress is associated with diseases of the modern life, including cancer, neurodegenerative 
diseases, rheumatoid arthritis, atherosclerosis, NAFLD, obesity, diabetes, the metabolic 
syndrome, and others (Sihvo et al. 2002, Willcox et al. 2004, Roberts and Sindhu 2009). 
Interestingly, GGT levels have been shown similarly to associate with many of these diseases. In 
the recent literature, GGT has also been shown to have an independent predictive value (that 
cannot be explained by its association with any of the other risk factors) at least for 
cardiovascular diseases and type 2 diabetes (reviewed recently in Targher 2010), and the 
metabolic syndrome (Nakanishi et al. 2004, Nannipieri et al. 2005, Jo et al. 2009, Ryu et al. 
2010). The mechanisms for such relationships have not yet been fully resolved. 
2.7.5.2 Aminotransferases (ALT, AST) 
Aminotransferases are measured primarily to assess the condition of the liver and are not as good 
indicators of excess drinking as GGT (Sillanaukee 1996). Serum alanine aminotransferase (ALT) 
originates rather specifically from the hepatocytes, whereas aspartate aminotransferase (AST) 
 31 
can also arise in clinically relevant activities from heart and skeletal muscle tissue (Pratt and 
Kaplan 2000). In an asymptomatic patient, the activities of serum aminotransferases may be 
increased at least due to alcohol abuse, medication, chronic hepatitis B and C, steatosis and 
NASH, autoimmune hepatitis, hemochromatosis, Wilson's disease (<40 years), Į1-antitrypsin 
deficiency, celiac sprue, genetic errors in muscle metabolism, acquired muscle diseases, and 
strenuous exercise, with some of these being easily ruled out by specific tests (Pratt and Kaplan 
2000). In addition, the interpretation of aminotransferases together may give specific 
information, as the activity of AST clearly over that of ALT is often supportive if alcoholic 
etiology is suspected (Nalpas et al. 1984, Salaspuro 1987, Sheth et al. 1998, Pratt and Kaplan 
2000). In association with heavy alcohol consumption and most other etiologies, increased 
aminotransferases are considered a hallmark of hepatonecrosis and liver damage.  
 
As with GGT, aminotransferases also seem to associate with general health so that ALT 
appears to have a much stronger association with BMI than with alcohol consumption (Adams et 
al. 2008). ALT associates especially with the hepatic fat content, and thus with NAFLD 
(Schindhelm et al. 2006) which, as a component of the metabolic syndrome, is highly related 
especially to the development of type 2 diabetes (Ghouri et al. 2010). In line with this view, 
several studies have shown that ALT has a predictive value on the aforementioned diseases, and 
apparently so even after an adjustment has been made for the classical risk factors (Vozarova et 
al. 2002, Hanley et al. 2004, Sattar et al. 2004, Hanley et al. 2005, Wannamethee et al. 2005, 
Goessling et al. 2008, Yun et al. 2009), although a few studies have also not found such 
independent associations (Nakanishi et al. 2004, Schindhelm et al. 2005). When considering 
possible pathologies, elevated serum ALT in NAFLD may be a consequence of leakage from the 
damaged hepatocytes or due to increased gluconeogenesis (alanine is an effective substrate) in 
the absence of insulin (Vozarova et al. 2002, Jadhao et al. 2004, Schindhelm et al. 2006).    
2.7.5.3 Uric acid 
Traditionally, uric acid is predominantly a marker of gout. It is an end product of purine 
metabolism in humans and in increased concentrations crystallizes in the joints, causing the 
disease. Both increased uric acid concentrations and gout are typical in alcoholics, which is due 
to increased adenine nucleotide turnover, related to metabolism of acetate to acetyl coenzyme A 
(energy for this reaction provided by adenosine triphosphate, ATP), and due to decreased renal 
excretion of uric acid, secondary to increased blood lactate levels (competition in tubular 
transport) (Puig and Fox 1984). Other reasons for hyperuricemia may be a high dietary intake of 
purine-rich foods (also including alcoholic beverages, especially beer), a high dietary fructose 
intake, conditions with elevated rates of cellular turnover, mutations in proteins involved in uric 
acid metabolism, reduced excretion by diseased kidneys, local ischemia, and circumstances 
associated with enhanced sodium reabsorption, such as a diuretic therapy, a low-sodium diet, 
obesity, insulin resistance or hyperinsulinemia, and hypertension (Strazzullo and Puig 2007, 
Lippi et al. 2008). 
 
Uric acid has also recently gained attention as a marker for oxidative stress (Becker 1993, 
Glantzounis et al. 2005), although its role in associated diseases still remains controversial. Uric 
acid is a major antioxidant accounting for up to 60% of serum free radical scavenging capacity 
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(Maxwell et al. 1997) and since its administration increases plasma antioxidant potential (Waring 
et al. 2001) and reduces exercise-associated oxidative damage in healthy volunteers (Waring et 
al. 2003), for instance, it has been hypothesized to be protective. On the other hand, uric acid has 
been suggested to become a pro-oxidant in certain situations (Patterson et al. 2003, Sautin and 
Johnson 2008), particularly when exceeding normal concentrations so that in these cases, the 
antioxidative properties are probably overwhelmed by the detrimental effects and the 
relationship becomes causal (Lippi et al. 2008). So far, the largest body of research has been 
gathered on the association between uric acid and cardiovascular diseases, but according to 
recent studies, there may also be an independent link between elevated serum uric acid and the 
development of the metabolic syndrome and its components (Strazzullo and Puig 2007, Lippi et 
al. 2008). 
2.8 Reference intervals of laboratory tests 
2.8.1 Concept, definition, determining 
Reference intervals provide a range of acceptable values for healthy individuals. These intervals 
serve as a basis for laboratory testing and are useful in determining whether the patient is well or 
not. If the result is not within the reference interval, the value is flagged in the laboratory 
information system (LIS) in order to indicate to the physician that the patient may need further 
examinations. 
 
The concept of reference values was originally introduced by Gräsbeck and Saris (1969) 
(Gräsbeck 2004). According to the International Federation of Clinical Chemistry and 
Laboratory  Medicine  (IFCC),  the  current  concept  of  reference  values  can  be  considered  at  
various levels (Solberg 1987): A reference individual is a healthy person fulfilling certain 
defined criteria. All those who would meet these criteria belong to a reference population, from 
which an adequate number of reference individuals is selected to form the reference sample 
group. A reference value is then measured from the reference individual of the reference sample 
group, and the statistical distribution of the reference values, the reference distribution, is used to 
produce the reference limits. Finally, the area between and including two reference limits is 
called the reference interval. 
 
A reference interval is usually defined as the interval that 95% of the reference values fall 
into,  leaving 2.5% of the reference values below the reference limit,  and 2.5% of the reference 
values above. The calculation of limits is mostly based on two methods, i.e., parametric and 
nonparametric analyses, although other methods have also been developed (Horn and Pesce 
2003). Parametric calculations estimate the reference intervals using a mean and two (exactly 
1.96) standard deviations (SD) of the data for a Gaussian distribution. If the distribution is not 
Gaussian, the data can be adjusted by, for instance, logarithmic or square root transformations. 
The mean ± 2SD is then calculated from the transformed data and the reference limits are 
obtained by transforming these back to the original units. This approach can be used only if the 
distribution of the data or transformed data is Gaussian. The nonparametric method, in turn, 
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makes no assumption about the distribution of the reference values. The values are simply 
ranked by ordering them from the lowest to the highest and the 2.5 and 97.5 percentiles are 
obtained as the 0.025 × (n + 1) and 0.975 × (n + 1) ordered observations. If the obtained values 
are not integers, then linear interpolation is carried out.  
 
In addition to properly selecting the calculation method, the size of the reference sample 
group is important to achieve a reasonable degree of precision. For the nonparametric method, at 
least 120 values are needed to produce the 90% confidence interval of the obtained limit, and at 
least this amount of reference values is also recommended by the Clinical and Laboratory 
Standards Institute (CLSI) (2008). At least 39 values are needed to produce the limit itself (with 
39 values, the limits become to the 1st and 39th values). For the parametric method, the reference 
limits and confidence intervals are calculable with even smaller sample sizes and in this regard, 
the quality management becomes more the responsibility of the investigator. 
2.8.2 The Nordic Reference Interval Project (NORIP) 
The modern lifestyle has created a need for a harmonization in reference intervals. Historically, 
the laboratories have been advised to establish their own reference intervals, which is, however, 
a highly demanding and costly process for a single laboratory to be performed according to the 
recommendations (Clinical and Laboratory Standards Institute 2008). In practise, laboratories 
have often used reference intervals obtained from the literature or have adjusted old intervals 
when introducing new methods in the laboratory. As a consequence, considerable variation has 
occurred in the reference intervals between laboratories. Recently, alongside advances in 
methodological consensus, the production of common reference intervals has become a potential 
approach to overcome these problems.  
 
The Nordic Reference Interval Project (NORIP) set out to establish common reference 
intervals for 25 of the most commonly measured properties in clinical chemistry (Rustad et al. 
2004a). The project was launched in March, 1998 in Oslo and supported by the Nordic Society 
of Clinical Chemistry (NFKK). The external quality assurance programs had shown that 
especially in Norway, the reference intervals for the same quantity in the same age and gender 
groups varied more than the corresponding analytical deviation could account for (Gadeholt 
2004). It was also believed that the population was too homogenous to allow for a biological 
variation. After the Norwegians were the driving force, and based on a decentralized design from 
Denmark, the NORIP project was a joint action of all five countries (Denmark, Finland, Iceland, 
Norway,  and  Sweden),  the  key  project  members  being  elected  by  the  national  societies  of  
clinical chemistry. At least 25 samples, evenly distributed on age and gender, were collected 
from a total of 102 Nordic laboratories mainly in 2000. In 2004, the project group published their 
recommendations for the common reference intervals after having concluded that partitioning by 
country was not necessary (Lahti 2004, Rustad et al. 2004a). Since then, these common reference 
intervals have been implemented in many, if not most, routine clinical chemistry laboratories in 
Finland.  
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3. Aims of the present research 
Health problems due to alcohol consumption and excess body weight are rapidly growing in our 
society. Although both heavy drinking and obesity are known to cause derangements in liver 
function and increased oxidative stress, the early-phase effects of ethanol intake and adiposity on 
the corresponding laboratory markers have remained less understood. 
 
 
The aims of the present work were as follows: 
 
1. To explore the effects of various levels of alcohol consumption on liver enzymes 
and proteins, and the effects of reference population selection on diagnosing heavy 
drinking 
 
2. To study the relationships between moderate drinking, excess body weight, and 
liver enzymes 
 
3. To study the relationships between moderate drinking, excess body weight, and uric 
acid 
   
4. To examine the impacts of moderate drinking and excess body weight on reference 
limits.  
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4. Materials and methods 
4.1 Subjects 
The subjects in these studies mainly consisted of those recruited for the NORIP survey, which 
was organized to establish common reference intervals for use in the Nordic countries (Rustad et 
al. 2004a). A total of more than 3,000 subjectively healthy individuals participated in this trial, 
and in addition to the blood samples, they provided data on a number of demographic 
characteristics, e.g., gender, age, ethnic origin, height and weight (self-report), alcohol 
consumption and smoking habits, menstrual status, use of estrogen preparations, and use of 
drugs or food supplements (Felding et al. 2004). The survey excluded individuals who had any 
evidence of current or recent illnesses, had consumed more than two standard drinks during the 
preceding 24 hours (one drink equivalent to 12 g of pure ethanol), had donated blood in previous 
five months, had diabetes (known or by survey results), were pregnant or breastfeeding, as well 
as most of those on prescribed drugs. A fasting (12 hours) state was recommended, and 
monitored by recording the time since the last meal. Smoking was not permitted one hour prior 
to sampling. 
 
The distributions of the study population across the most relevant characteristics are shown in 
Table 1.  The data from Sweden were excluded from these calculations,  as well  as from all  the 
analyses in the present study, due to the inapplicable questioning of ethanol consumption 
(Felding et al. 2004). In addition, only subjects reporting 0 measures of alcohol per week (later 
referred to as abstainers) or 1–21 measures/week (moderate drinkers) were qualified from the 
other countries. The assessment was conducted by asking, "Do you normally drink 0, 1–21, or 
more than 21 measures of alcohol per week?" (0.5% more than 21 measures/week, 1.0% 
unanswered). In the final study sample, 96% of the subjects were of Nordic origin, 80% were 
non-smokers (3% unanswered), and 76% had not used drugs or food supplements (5% 
unanswered).  
 
In addition to the NORIP participants, study I also included 133 heavy drinkers. This sample 
consisted of 105 men (age 45 ± 10 years) and 28 women (age 43 ± 11 years) who had been 
admitted for detoxification. They all showed a history of continuous or binge drinking, the mean 
alcohol consumption having been 64 (range 23–315) measures/week from the period of  4 weeks 
prior to the sampling, as assessed by questionnaires asking the number of standard drinks 
consumed during the last 24 hours, 1 week and 4 weeks. None of these heavy drinkers had any 
known liver disease or apparent symptoms of such a condition. 
 
In study IV, which focused on the assessment of reference intervals for different groups, 
several further exclusion criteria to the above mentioned a priori rules  were  used.  These  were  
both analytical and individual aspects, which followed those applied to the calculation of the 
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NORIP recommendations (Rustad et al. 2004a). With respect to the analytes in the present study, 
the most common reason for rejection was the incompatibility of the methods used for the 
analysis of liver enzymes with the IFCC primary reference procedures (Schumann et al. 2002a, 
Schumann et al. 2002b, Schumann et al. 2002c, Strømme et al. 2004). It is likely that the data not 
fulfilling this criterion (13–46%) have biases that are both negative and positive so that the rest-
effect would be an increase in variance, widening the reference intervals. These results can, 
however, be expected to distribute across the population, and therefore in studies I–III, such 
procedures were not used in order to maintain as large a data as possible. Furthermore, for GGT 
in  paper  IV,  results  were  rejected  only  for  person  exclusion  criteria,  as  the  number  of  IFCC-
compatible measurements for this analyte was too few to enable the study purposes. The 
distributions of GGT for the IFCC- and non-IFCC-compatible method types were ascertained as 
being essentially identical for high values, which should indicate that combined data could be 
used for reference interval calculations. 
 
 
Table 1. Population characteristics. The data are percentages (%), except for age (mean ± SD). 
 
Characteristic Male Female 
Gender 47 53 
Age 47 ± 18 46 ± 17 
Body mass index (BMI, kg/m2)   
<19  1 5 
19–25 54 69 
25–30 41 22 
>30 4 4 
Alcohol consumption (measures/week) 
0  25 38 
1–21 75 62 
4.2 Ethical aspects 
The NORIP project was approved by the ethics committees in each of the five Nordic countries 
(Felding et al. 2004) and the studies on heavy drinkers were approved by the Ethics Committee 
of the Seinäjoki Central Hospital, Finland. All research was carried out according to the 
provisions of the Declaration of Helsinki.  
4.3 Measurements of laboratory markers 
The measurements for the individuals representing the NORIP material were carried out between 
1999 and 2001 in several Nordic routine clinical biochemistry laboratories, including the 
laboratory at the Seinäjoki Central Hospital (accredited according to SFS-EN ISO/IEC 17025). 
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The measurements were performed on thawed samples (stored at –20 °C for up to one month) in 
one series. Agreement between laboratories was ascertained by an analysis of the calibration 
material together with the samples and adjustment of the results to meet a common level in case 
of non-enzyme analytes; for enzymes, only the results obtained by assay conditions at 37 °C 
which were compatible with and traceable to IFCC reference methods were included (Rustad et 
al. 2004a). The measurements from heavy drinkers were performed locally at Seinäjoki and 
applying the same procedures for harmonization. 
4.4 Statistical methods 
The SPSS 13.0 and 15.0 packages were used for the statistical analyses (SPSS Inc., Chicago, IL, 
USA), and a two-sided p-value <0.05 was taken as the level for statistical significance. The 
correlations were calculated as Pearson correlations for continuous Gaussian distributed 
parameters and as Spearman correlations if one or both parameters were categorical or skewed. 
The differences between correlations were analyzed with the z-test for correlation coefficients. 
The comparisons of frequency data were made using the Ȥ2-test. The comparisons between two 
groups regarding parameters with Gaussian distributions were made by the t-test, and the 
comparisons between groups with skewed distributions with the Mann-Whitney test. Three or 
more groups were compared using one-way analysis of variance (ANOVA) and the Bonferroni 
post hoc test in case of Gaussian distributions and equal variances. Otherwise, the analyses were 
made with the Kruskal-Wallis test and the Tamhane's T2 post hoc test. The interactions among 
gender, drinking habits and BMI on different biomarkers were analyzed using factorial ANOVA. 
Linear regression was used to assess the proportion of variability and to determine the predictors 
of laboratory values. For factorial ANOVA and linear regression, a mathematical transformation 
was performed for skewed analytes to meet the prerequisites of these tests. 
 
In paper IV, the Analyse-it 2.11 for Microsoft Excel (Analyse-it Software Ltd., Leeds, UK) 
was also used to calculate the reference limits. The limits were always calculated as 2.5 and 97.5 
percentiles, similarly to the NORIP protocol (Rustad et al. 2004a). On the contrary, enzyme 
outliers were not excluded by identification of results lying outside the mean ± 4SD of the 
gender specific logarithmic data, but by performing the Dixon's outlier test for each reference 
data set separately (Dixon 1953, Clinical and Laboratory Standards Institute 2008). The Dixon's 
test identifies an extreme value as an outlier if the difference between the extreme and the next 
extreme value exceeds one third of the range of values in the sample. In study I, the upper 
reference limits for albumin and transformed ferritin were also calculated parametrically as the 
mean + 2SD. 
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5. Results 
5.1 Effects of various levels of drinking and gender on liver 
enzymes, albumin, and ferritin (I) 
In paper I, the levels of liver enzymes (GGT, ALT, AST) and proteins (ferritin, albumin) in 
serum were compared in a large population of abstainers, moderate drinkers and heavy drinkers. 
A significant correlation (r >0.3) was found between the self-reported ethanol consumption and 
four of the five analytes (GGT, r = 0.50; ALT, r = 0.39; AST, r = 0.45; ferritin, r = 0.49;             
p <0.001 for all). In the comparisons between groups, male heavy drinkers showed significantly 
higher (p <0.001) values than both abstainers and moderate drinkers in all the variables, and also 
between abstainers and moderate drinkers in their GGT (p <0.001) and ALT (p <0.05). In 
women, heavy drinkers similarly showed the highest values, although somewhat less 
pronounced, but no significant differences between abstainers and moderate drinkers were noted. 
 
This study also explored the influence of reference population selection on the reference 
limits and diagnosis of heavy drinking. Again, marked differences were found for the liver 
enzymes and ferritin, especially for men, in whom the increase from the upper reference limits 
based on abstainers to the limits based on moderate drinkers varied between 15% for AST and 
68% for GGT, as calculated from Table 2. Among women, an increase was noted for ferritin and 
GGT, these being 35% and 25%, respectively.  
 
 
Table 2. The upper reference limits for liver enzymes and proteins based on either abstainers or 
moderate drinkers as the reference population. 
 
 Upper reference limit 
 Men  Women 
Analyte Abstainers  Moderate drinkers  Abstainers  Moderate drinkers 
Ȗ-Glutamyltransferase (GGT, U/l)  63 106 63 79 
Alanine aminotransferase (ALT, U/l) 58 73 49 48 
Aspartate aminotransferase (AST, U/l) 39 45 41 37 
Ferritin (µg/l) 274 342 141 191 
Albumin (g/l) 47 48 46 46 
 
 
Table 3 compares the marker-specific sensitivities resulting from the different reference 
limits. As expected, the abstainer-based limits identified more heavy drinkers with increased 
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values than the limits based on moderate drinkers. In addition, up to 9% of moderate drinkers 
also showed values above the limit. If the data using these lower limits were reported for genders 
separately, the proportions were slightly higher for men and on average about one-third lower for 
women, compared to those presented in the table. When using the limits from moderate drinkers, 
the decrease in diagnostic power was more obvious in men than in women. 
 
 
Table 3. The percentage of heavy drinkers exceeding the limits from the different reference 
populations. 
 
% of heavy drinkers with value above ref. limit 
Analyte                Reference population ĺ        Abstainers Moderate drinkers 
Ȗ-Glutamyltransferase (GGT)  62 40 
Alanine aminotransferase (ALT) 39 30 
Aspartate aminotransferase (AST) 53 50 
Ferritin 34 27 
Albumin 20 13 
5.2 Effects of moderate drinking and BMI on liver enzymes (II) 
and uric acid (III) 
Paper II studied the effects of both drinking habits and BMI on the liver enzymes in abstainers 
and moderate drinkers, and found the effects of excess body weight and alcohol consumption 
parallel. When the participants were classified into subpopulations, each subgroup with a higher 
BMI had higher mean enzyme activities, and the activities in moderate drinkers were higher than 
those in the group of abstainers with the same BMI. The highest mean levels were thus found in 
obese moderate drinkers. The effects of these two lifestyle factors were especially strong for 
GGT and ALT in men (Figure 2). 
 
In statistical analyses, the interactions between the BMI and drinking status did not reveal 
significance for any of the enzymes, i.e., the effects were additive. Interestingly though, for 
example, for GGT in men, the activities in obese moderate drinkers were higher than expected 
from the separate effects of an increased BMI and moderate drinking: compared to normal 
weight abstainers,  the mean GGT activities were increased by 24% in normal weight moderate 
drinkers, by 36% in obese abstainers, and by 116% in obese moderate drinkers (theoretically 
1.24 × 1.36 = 1.69, which is less than 2.16, i.e., less than an increase of 116% (calculated from 
Figure 2)). Also the correlation coefficient between the BMI and the enzyme level was 0.32      
(p <0.001) in moderate drinking men, whereas only 0.22 in abstainers (p <0.01). 
  
The observations on mean enzyme activities and the differences in partial correlations further 
indicated that GGT may be dependent more on ethanol intake and that ALT may be more 
strongly associated with BMI. For GGT, the increase in enzyme activity from abstainers to 
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Figure 2. The activities (mean + SD) of Ȗ-glutamyltransferase (GGT), alanine aminotransferase 
(ALT), and aspartate aminotransferase (AST) according to the BMI and drinking habits. 
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moderate drinkers among overweight men was 38%, whereas only 19% for ALT. In those with 
normal weight, they were the previously mentioned 24% for GGT and 8% for ALT. In the partial 
correlations controlling for drinking status, the correlation coefficient for an association between 
the BMI and the enzyme activity was higher for ALT (r = 0.31, p <0.01) than for GGT (r = 0.23, 
p <0.01). 
 
In addition, the ratio of AST to ALT varied greatly in this study population as a function of 
the two lifestyle factors. The ratio >1 was significantly less common in moderate drinkers than in 
abstainers (p <0.002), and in overweight individuals than in normal weight individuals               
(p <0.001). Among the BMI subgroups, the distributions showed significant differences 
according to drinking status in participants who were underweight (p <0.05 for the higher portion 
of ratios >1 among moderate drinkers) and overweight (p <0.001 for the lower portion of ratios 
>1 among moderate drinkers). 
 
Paper III studied the effects of moderate drinking and BMI on uric acid and predominately 
found very similar patterns to those with the liver enzymes. At maximum, the mean 
concentrations were increased by about one-third (Figure 3). The concentrations of uric acid also 
correlated with the liver enzymes, the strongest correlation being with GGT (r = 0.41; ALT,        
r = 0.32; AST, r = 0.32; p <0.001 all). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The concentrations (mean + SD) of uric acid according to the BMI and drinking 
habits. 
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5.3 Gender-dependent effects of moderate drinking and BMI on 
liver enzymes (II) and uric acid (III) 
Gender issues were specifically addressed in papers II and III. In paper II, the effects of excess 
body weight and alcohol consumption were noticed not to be equal in men and women. The 
mean enzyme activities (Figure 2) and the correlations in different groups suggested the male 
subjects to have stronger positive associations especially between moderate drinking and enzyme 
levels. Accordingly, the 2-factor interactions of drinking status × gender were statistically 
significant for each enzyme (GGT, p <0.001; ALT, p <0.05; AST, p <0.05). 
 
Paper III examined the effects of BMI and moderate drinking on uric acid, and found both 
effects to be different with respect to gender. The mean uric acid concentration increased as a 
function of an increasing BMI regardless of sex (Figure 3), but in women, this association was 
stronger. The correlation coefficients were 0.38 and 0.27 for women and men respectively, their 
difference being significant (p <0.02). In the BMI-specific comparisons between drinking habits, 
men showed significantly higher concentrations in moderate drinkers than in abstainers among 
those with normal weight (p <0.001), whereas in the other groups the concentrations did not 
differ significantly. In women, the concentrations were unchanged or even decreased slightly. 
Moreover, the factorial analyses showed interactions between gender and the BMI (p <0.02), and 
between gender and drinking status (p <0.001). In addition, the interaction between the BMI and 
drinking status was nearly significant in men (p = 0.056).  
 
Among women age also influenced their variation in uric acid. In women, nearly 9% of the 
variation was due to age, whereas in men, the effect was virtually absent (0.1%). Interestingly, 
the menopausal status appeared to determine not only the uric acid concentrations, but also the 
drinking-related changes. First, the concentrations of uric acid were significantly (p <0.001) 
higher in the subgroup of postmenopausal women (>60 years and without any estrogen 
medication) as compared to the subgroup of premenopausal women (<40 years and without any 
estrogen medication). Second, in the BMI-specific comparisons of these subjects, the decrease in 
concentration by alcohol drinking was noted significant in normal weight premenopausal women 
(p = 0.024), whereas this was not noted in normal weight postmenopausal women. However, in 
the overweight groups, neither of the comparisons was significant. 
5.4 Effects of body weight and alcohol consumption on the 
population-derived reference intervals (IV) 
Study IV included a large panel of analytes which had been shown to differ according to the 
BMI in the NORIP population (Rustad et al. 2004b), and examined the effects of body weight 
and drinking habits on their upper reference limits. The co-existence of excess body weight and 
moderate drinking in a reference population influenced the upper limits of several biomarkers, 
and moderate drinking alone influenced the upper limits of GGT and ALT. When the upper 
limits calculated from moderate drinkers with a BMI of >27 kg/m2 were compared against  the 
limits from normal weight abstainers, marked changes were noted for GGT (+11% – +186%), 
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ALT (+51% – +146%) and AST (0% – +30%), but also for total cholesterol, creatine kinase, 
fasting glucose, HDL-cholesterol, fasting triglycerides, and uric acid. When normal weight 
moderate drinkers and the corresponding abstainers were compared, the differences were    
+13% – +74% for GGT and +14% – +27% for ALT. Statistically, alcohol drinking was a 
significant predictor variable of GGT, total cholesterol (50 years) and uric acid in men, and of 
HDL-cholesterol in both men and women, but not of ALT in either sex. 
 
The impacts of a high BMI and alcohol drinking were also studied by calculating the relative 
risks of increased values for different subgroups. When the reference limits from normal weight 
abstainers were used as a baseline, the portion of liver enzyme activities above the limit 
gradually increased from this baseline to normal weight moderate drinkers, to overweight 
abstainers, and to overweight moderate drinkers, respectively. The trend was clearer in men than 
in women. At its greatest, the portion (relative risk) in men was 3–7-fold as compared to the 
theoretical 2.5% in normal weight abstainers, being the lowest for AST and the highest for GGT. 
A similar pattern and a more than 3-fold higher risk were also found for uric acid. In addition, 
changes were seen in serum lipid profiles (total cholesterol; HDL-cholesterol, for which risks 
were assessed by values below the lower reference limit; and triglycerides), but these were not as 
prominent as for the liver enzymes. 
 
Table 4 summarizes the upper reference limits from normal weight abstainers and contrasts 
them to the NORIP recommendations. It appears that an increase of up to 82% and 67% in GGT 
(men <40 years, men 40 years) and 40% in ALT (men) occurs for the currently recommended 
limits by excess body weight and alcohol consumption. Respectively 9.2%, 7.6% and 7.2% of 
the corresponding NORIP participants had a value greater than the limits calculated here. 
 
 
Table 4. The upper reference limits of liver enzymes according to the NORIP recommendations 
and as calculated from normal weight abstainers. 
 
 Upper reference limits 
Analyte Recommendation (NORIP) Normal weight abstainers 
Ȗ-Glutamyltransferase (GGT, U/l) 
Men <40 years  80   44 (n = 59) 
Men 40 years  115  69 (n = 64) 
Women <40 years   45  38 (n = 88) 
Women 40 years  75  75 (n = 145) 
Alanine aminotransferase (ALT, U/l) 
Men  70  50 (n = 109) 
Women   45  37 (n = 217) 
Aspartate aminotransferase (AST, U/l) 
Men  45  40 (n = 100) 
Women  35  40 (n = 192) 
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6. Discussion 
6.1 Different levels of drinking and markers of liver status (I) 
Study I was conducted on a population with a wide range of alcohol consumption and the results 
show that excessive alcohol drinking, even in individuals without apparent liver disease, can 
induce the activities of liver-derived enzymes (GGT, ALT, AST) and elevate the concentrations 
of hepatic proteins (ferritin, albumin). Moreover, the marker levels may differ already by 
moderate consumption. When the reference limits from abstainers were further used as a 
baseline, not only were more heavy drinkers diagnosed as having values above the limits, but an 
increased portion of moderate drinkers also exceeded these limits. This knowledge on the early-
phase alterations is important in an effort to improve the effectiveness of diagnosing heavy 
drinking. Subsequently, action can be taken to reduce consumption (Kaner et al. 2007, McQueen 
et al. 2009) and thereby to prevent the onset of health hazards or their progression, in that with 
abstinence, the survival rate in ALD is usually fairly good (Diehl 1998, Mann et al. 2003). 
 
Interestingly, many of the marker elevations observed here may be linked to the processes of 
oxidative stress. For instance, GGT is critical for maintaining glutathione, an antioxidant of the 
cells, and as such, GGT-deficiency results in oxidative stress and a susceptibility to oxidative 
injury (Zhang and Forman 2009). By breaking down extracellular glutathione into its constitutive 
amino acids, GGT helps to provide cysteine, the rate-limiting amino acid, for cellular glutathione 
synthesis. Similarly, elevated serum ferritin (iron-storage protein) has been suggested to reflect 
increased body defence against the oxidative stress caused by excess free iron, but as well by 
other stressors (Lee and Jacobs 2004). Given that alcohol consumption is a well known inducer 
of oxidative stress (Lieber 1997) and that even mild to moderate alcohol consumption has been 
shown to elevate the indices of iron stores (Ioannou et  al.  2004),  both mechanisms may play a 
role in the present study population. Finally, elevated values were also noted for albumin, which 
is quantitatively the most important circulating antioxidant (Roche et al. 2008). Due to this 
antioxidative nature and to the fact that oxidative stress can significantly modify albumin, 
affecting its biological function (Arroyo 2009), it could be hypothesized that albumin is 
increased to keep up with the increased need. Usually, however, increased oxidative stress has 
been found to associate with decreased total albumin (Bito et al. 2005), whereas a relationship 
between increased albumin (albumin is a negative acute-phase reactant) and the anti-
inflammatory effects of alcohol has been suggested (Imhof et al. 2001, Imhof et al. 2004). Such 
effects may relate to the more direct consequences of ethanol or its metabolites on gene 
expression, e.g., through the modulation of transcription factor activity (Mandrekar et al. 1996, 
Mandrekar et al. 2006). It also cannot be excluded as to whether the other above effects were at 
least in part due to similar ways, since various epigenetic modifications by alcohol drinking are 
possible as well, and the understanding of them is only beginning to emerge (Shukla and Aroor 
2006). 
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The relative sensitivities of the liver enzymes in detecting heavy drinking were as expected. In 
accordance with several lines of literature, GGT was most often elevated, followed by AST and 
ALT (Sillanaukee 1996, Salaspuro 1999). Also in line with recent work by others, ALT had the 
strongest association with the BMI (study II) (Schindhelm et al. 2006, Adams et al. 2008). 
6.2 Moderate alcohol consumption and excess body weight (II, 
III) 
According to study II, the liver enzyme activities were also markedly influenced by excess body 
weight so that i) the mean enzyme activities increased with an increasing BMI and already by 
overweight, and that ii) the effects of an increased BMI and moderate drinking were additional to 
each other. Significant BMI × drinking status interactions were not found by the corresponding 
statistical tests, although several other observations were supportive. Briefly, the enzyme levels 
in obese moderate drinkers were higher than estimated from the isolated additive effects of 
obesity and drinking, and the correlation coefficients between the enzyme levels and the BMI 
were stronger in moderate drinkers than in abstainers. In addition, the ratios of AST ÷ ALT were 
significantly lower in moderate drinkers than in abstainers among overweight but not normal 
weight subjects, which further supports the view that the effects of alcohol are not equal with 
normal and excess body weight. Previously, only a few of the studies that have addressed the 
potential modification by adiposity on the effects of alcohol have been population-based, but 
those published have noted statistically significant positive interactions between alcohol and the 
BMI on the liver enzyme levels (Poikolainen and Vartiainen 1997, Ruhl and Everhart 2005, 
Loomba et al. 2009), except for Adams et al. (2008), yet with the difference that in these studies, 
as opposed to the current data, heavy drinkers were not excluded from the analyses. 
 
The ratios of the transaminase enzymes (AST ÷ ALT) are generally helpful in the differential 
diagnosis of alcoholic liver damage as compared to those with non-alcoholic damage, or in 
predicting fibrosis in non-alcoholic steatohepatitis (NASH), but in the present study, differences 
were also noted among apparently healthy individuals with only mild changes in their ALT and 
AST activities. Typically, the ratio of AST to ALT over 1.5–2.0 is suggestive of alcoholic 
etiology (Cohen and Kaplan 1979, Salaspuro 1987), whereas in non-alcoholic etiology, the ratio 
is usually less than one, although it increases as fibrosis advances (Angulo et al. 1999, Sorbi et 
al.  1999).  In  the  present  series,  the  ratios  were  lower,  i.e.,  ALT  exceeded  AST  more  often  in  
overweight individuals than in those with normal weight, and also (paradoxically) in moderate 
drinkers than in abstainers. In adiposity, a high ALT is considered to mark fat accumulation in 
the liver (Schindhelm et al. 2006), but the reason for this increase in moderate drinkers remains 
to be elucidated. In more advanced liver disease, the predominance of AST over ALT may be 
explained by a depressed hepatic ALT activity due to a drinking-related deficiency of pyridoxal-
5'-phosphate (vitamin B6, an enzyme cofactor) (Diehl et al. 1984), which often, however, is 
supplemented in an assay mixture (supplemented in here), or by hepatic mitochondrial damage 
(Nalpas et al. 1984) and skeletal or cardiac muscle injury (alcoholic myopathy), which release 
AST into the circulation. Irrespective of the etiology, there may also be disturbances in the 
hepatic clearance of AST through the sinusoidal liver cells (Sheth et al. 1998). 
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The observations on uric acid in study III support the interpretation of an increased oxidative 
stress level in alcohol consumers discussed under 6.1. Uric acid has recently been proposed as a 
marker of oxidative stress (Becker 1993, Glantzounis et al. 2005), and in the present study, 
moderate  drinking  as  well  as  excess  body  weight  were  found  to  produce  similar  patterns  of  
increases on its concentrations than on the liver enzyme activities. On the other hand, it could be 
argued that various other factors also may have affected the uric acid concentrations. For 
example, these factors include a high fructose intake, purines in alcoholic beverages and 
decreased excretion due to obesity and related conditions (Strazzullo and Puig 2007, Lippi et al. 
2008). Nevertheless, several studies have shown increased oxidative stress in obesity (Keaney et 
al.  2003)  and  also  associations  of  GGT  and  ALT  with  the  direct  markers  of  oxidative  stress,  
independent of the metabolic syndrome (Yamada et al. 2006).  
6.3 Gender issues (II, III) 
The ethanol-related changes in the liver enzymes appeared to occur in a gender-dependent 
manner (study II). The interaction analyses indicated the positive associations between alcohol 
consumption and the liver enzyme activities to be stronger in men than in women. In general this 
observation is in line with the fact that susceptibility to alcohol-relates adverse health effects 
vary according to sex. However, this would then suggest inverse kinetics between the enzyme 
levels and tissue pathology when considering that the risks are known to be higher in women 
rather than men (Becker et al. 1996, Schenker 1997). In other words, it is as if men were 
protected by their greater increases in the enzyme activities. Although it may well be that GGT, 
due to its role in maintaining the antioxidative glutathione (Zhang and Forman 2009), is induced 
in an effort to confer protection against the harms of alcohol, it should still be considered to 
reflect the degree of tissue damage or burden, and not the efficacy of defence. It is also possible 
that the present observations could be explained by differences in alcohol consumption levels. 
The NORIP protocol assessed drinking habits categorically, and thus within a same category, the 
true amounts consumed may differ for men and women.  
 
It is tempting to speculate that the gender difference in the effects of alcohol on uric acid 
(decreased concentrations in women and increased concentrations in men) that was observed in 
study III, could predispose women to greater risks of alcohol-related health hazards. The 
hypothesis is supported by the following rationalization: 1) The concentration of serum uric acid 
is influenced, among others, by nitric oxide, which is an inhibitor of the uric acid synthesizing 
pathway (Pitocco et al. 2008); 2) Nitric oxide in turn is important in maintaining normal vascular 
function, and is inducible by estrogen (Qiao et al. 2008). Accordingly to points 1 and 2, uric acid 
seems to increase during menopause when the relative cardioprotection of premenopausal 
women as compared to men of the corresponding age is lost (Maxwell 1998); The next point, 3), 
given that alcohol intake can increase both pre- and postmenopausal estrogen (Ginsburg 1999, 
Onland-Moret et al. 2005), it may be suggested that alcohol consumption could, through 
increasing nitric oxide, eventually lead to lowered uric acid in women, as was noticed here 
particularly among premenopausal normal weight women. Unchanged uric acid in normal 
weight postmenopausal women could be due to the unresponsiveness of estrogen receptors, 
which has recently been proposed to account for the lack of vascular benefits of hormone therapy 
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for aging women (Meyer et al. 2008, Qiao et al. 2008). In overweight or obese women, excess 
body weight probably overpowers the impact of moderate alcohol intake, as seen also with men, 
in whom the increase in concentration from abstainers to moderate drinkers was noted to be 
significant among those having normal weight but not among overweight individuals; And 
finally point 4), to conclude, it remains to be established whether nitric oxide increases due to 
moderate alcohol intake and associates with beneficial cardiovascular effects specifically in 
normal weight premenopausal women and whether the related decrease in uric acid renders these 
women at the same time more susceptible to damage in other tissues, such as the liver. It is 
important to note, however, that the latter conclusion is based on the assumption of the 
antioxidative effects of uric acid.  
 
Study III also demonstrated a gender difference in the effects of the BMI on uric acid, i.e., the 
association was stronger in women than in men. Thus far, the mechanisms behind the difference 
seem to be unknown, and studies addressing this issue more specifically are needed to elucidate 
the phenomenon. Interestingly though, the link between uric acid and diabetic findings or 
coronary heart disease has also been suggested to be stronger in women than in men (Fang and 
Alderman 2000, Chou et al. 2001, Lin et al. 2004, Kodama et al. 2009), yet conflicting data also 
exist (Wheeler et al. 2005). 
6.4 Upper reference limits (IV) 
Paper IV summarized the findings in studies I–III and showed that moderate drinking and excess 
body weight markedly influence the current liver enzyme reference limits. Based on the data 
obtained from normal weight abstainers, the upper reference limit for GGT in men <40 years 
would be around 44 U/l, while the current recommendation is 80 U/l. For men 40 years, the 
limit would be 69 U/l instead of the current 115 U/l. And also for ALT, the limit from normal 
weight  abstaining  men  was  found  to  be  50  U/l,  as  against  the  recommended  70  U/l.  It  is  
interesting to note that, before the establishment of the NORIP reference limits in 2004, the 
common limits in men were 80 U/l  for GGT (all  ages),  and 50 U/l  for ALT. Moreover,  in the 
early 1990s, the limit for GGT in men was only 50 U/l. 
 
Establishing reference intervals that take into account the individual's BMI and drinking 
habits would undoubtedly have both benefits and drawbacks. If reference limits were set 
separately, e.g., for BMI-subgroups, it could easily cause confusion, especially in case the limits 
were not very different. The NORIP project also reported differences in the upper limits for GGT 
and ALT between the subjects with a BMI above and below 28 kg/m2, but considered these 
modest and did not suggest separate limits (Strømme et al. 2004). On the other hand, producing 
higher limits for the adipose subjects would seem inappropriate in considering the increased liver 
enzyme activities to nonspecific biochemical interference (Prati et al. 2002). Alternatively, the 
problems related to heterogeneity of a reference population could be handled by producing the 
reference limits from a single population by strengthened inclusion criteria, as has also been 
suggested by Prati and colleagues (2002) (Kaplan 2002, De Rosa et al. 2003, Senior 2003).  
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Several reasons support the view that increasing criticism in selecting reference populations 
would yield benefits that are greater than the possible expenses caused by the increased 
frequency of values above the limits. First, the detection of the early changes in the liver enzyme 
activities may be important for the early detection of heavy alcohol consumption. At least before 
the  full  onset  of  an  epidemic  of  obesity,  experts  considered  roughly  70%  of  the  cases  of  
increased GGT activity to be explained by excessive drinking (Sillanaukee 1996, Käypä hoito 
2010). Nevertheless, it should be noted that there are a number of more sensitive and specific 
markers (e.g., EtG/EtS, CDT, PEth, FAEE), which ideally would often be more preferable when 
the investigation of alcohol consumption or lack thereof is the main reason for testing, whereas 
the liver enzymes rather perform at best to prompt the suspicion of excess use.   
 
Second, mild to moderate increases in aminotransferases are often a sign of NAFLD, which is 
currently recognized as the hepatic manifestation of obesity and the metabolic syndrome, and 
which in itself also has possible detrimental consequences (Matteoni et al. 1999). Clark et al. 
(2004) found nearly 70% of the aminotransferase elevations unexplained by traditional causes 
(alcohol, hepatitis B or C, or iron overload), and suspected most of these being caused by 
NAFLD. In addition, increased reference limits may affect the referral for a liver biopsy when 
considering that the level of aminotransferases repeatedly more than twice the upper limit has 
been recommended as the decision-making point, for example, in cases of an unknown cause to 
rule out serious disorders  (Pratt and Kaplan 2000) or in NAFLD-suspects to distinguish those 
needing the closest follow-up (Day 2002, Kaplan 2002, McNair 2002). Similarly, the established 
reference limits may affect the management of various other conditions (Pratt and Kaplan 2000).  
 
Third, the liver enzymes have also recently emerged as markers of general well-being. But 
rather than simply increasing as a consequence of, for instance, alcohol consumption or obesity, 
changes in the liver enzymes (and in uric acid) seem also to have an independent predictive 
value for cardiovascular diseases, type 2 diabetes, and for the metabolic syndrome (Vozarova et 
al. 2002, Hanley et al. 2004, Nakanishi et al. 2004, Hanley et al. 2005, Nannipieri et al. 2005, 
Strazzullo and Puig 2007, Lippi et al. 2008, Jo et al. 2009, Targher 2010). The reasons for these 
independent associations are currently not known. They can be a reflection of so early changes 
that cannot be observed by any current outcome measures. Or, they can be a reflection of thus far 
undiscovered disease mechanisms (Ioannou 2008). These biomarkers can as well be the real 
culprits in disease development, as suggested in the case of increased uric acid concentrations 
(Lippi et al. 2008), but also in fact for GGT in atherosclerotic plaques (Paolicchi et al. 1999). On 
the other hand, independent-looking associations may also emerge owing to the imperfectness of 
controlling measures such as the BMI or waist circumference (Ioannou 2008) or because of not 
knowing what to control for. Recently, Lee and Jacobs (2009) suggested that the association of 
GGT with many diseases may reflect the harmful effects of background exposure to various 
environmental pollutants. Nevertheless, whether causal, protective, or inert, the higher the levels 
of the liver enzymes and uric acid become, the higher the risks apparently are, and therefore the 
aim should be to modify the factors that are known to elevate these markers and that one can 
have an influence on (Ioannou 2008). Moreover, prediction has also been shown with those 
values clearly below the currently recommended reference limits (Sattar et al. 2004, 
Wannamethee et al. 2005, Goessling et al. 2008, Yun et al. 2009, Ryu et al. 2010, Targher 2010). 
And finally, another important argument is that an objective proof of unhealthy lifestyle may 
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motivate change. Altogether these reasons clearly suggest that an effort should be made to 
prevent the increase in the liver enzyme upper reference limits. 
 
The  data  here  also  showed  changes  in  the  serum  lipid  profiles  as  a  result  of  moderate  
drinking. The most interesting was the increased HDL-cholesterol concentration, which in 
several studies has been suggested to play a role in the positive impacts of moderate alcohol 
intake on cardiovascular mortality (Rimm et al. 1999, Mukamal et al. 2005). In addition, 
drinking can also affect the composition and function of HDL-cholesterol (Brinton 2010). 
However, given that the sensitivity of the liver to alcohol consumption in general appears to be 
greater than perhaps previously anticipated, the changes in liver status by moderate drinking may 
exceed the benefits observed for other organs. Apparently, further studies are warranted on this 
matter. 
6.5 Possible limitations of this study 
In practice, all scientific studies entail some limitations. In the present study, the possibility of 
some erroneous classification of alcohol consumption cannot be excluded. The permitted alcohol 
intake were similar for women and men in the NORIP protocol, and may have led to the 
misclassification of some female individuals who were in fact on the edge of excessive 
consumption rather than true moderate drinkers. Moreover, since the alcohol consumption data 
were based on the subjects' own assessments, some underreporting may have taken place 
throughout the population as well. Whether some misclassification happened or not, e.g., some 
moderate drinkers were true excessive drinkers, it however does not affect the key observation 
on the reference limits but, if anything, it underscores the need for better control in qualifying 
reference individuals. 
6.6 Future considerations 
The findings of this study provide evidence that the diagnosis and prevention of liver problems 
could be improved by better taking into account and understanding the effects of different factors 
on related biomarkers. In addition to BMI (or perhaps preferably waist circumference) and 
alcohol consumption, other factors can also influence the liver enzyme activities, such as 
smoking, coffee consumption and ethnic origin. According to recent studies, there might be 
synergism between the effects of alcohol consumption and smoking on the liver enzymes, and 
thus possible aggravation of the related health hazards (Whitehead et al. 1996, Breitling et al. 
2009, Wannamethee and Shaper 2010). On the other hand, the protective effect of coffee 
drinking is an interesting field of study in Finland (Poikolainen and Vartiainen 1997, Bidel et al. 
2008, Hu et al. 2008), as Finns are some of the highest consumers of this beverage in the world. 
Furthermore, both the baseline liver enzyme activities and the susceptibility to induction by 
alcohol or obesity may differ between races (Horn and Pesce 2002, Stewart 2002, Horn and 
Pesce 2003, Stranges et al. 2004, Samadi et al. 2007). With increasing international mobility, 
recognizing these differences is becoming more and more important. 
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In respect of establishing reference limits based on more carefully defined populations, it 
should be noted that for some analytes in the present study, the limits for normal weight 
abstainers were calculated from a relatively small number of individuals. In these cases, the 
corresponding upper limits provided here should be considered as estimates warranting more 
studies in larger populations to set the exact boundaries. In ideal future scenarios, the results of 
those studies and the gathering of information on the links with the diseases of affluence would 
further translate into a diagnosis of increased oxidative or metabolic burden when exceeding a 
certain threshold value of liver enzyme activity. 
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7. Conclusions 
The summary of and conclusions to be drawn from the main findings in the present series are as 
follows: 
 
1. The biomarkers of liver status may respond to even moderate drinking. If the 
reference limits were based on moderate drinkers, the diagnosis of heavy drinking 
is also compromised. Consequently, only abstainers should be included in the 
reference populations in order to achieve the best sensitivity for these tests used to 
detect alcohol abuse. 
 
2.  The liver enzyme activities increased as a function of body weight throughout the 
BMI scale, and the activities were yet higher in moderate drinkers than in abstainers 
with a corresponding BMI. The statistical results were not significant for the 
interactions between the effects of moderate drinking and the BMI, although the 
mean activities in moderate drinkers with an increased BMI were slightly higher 
than expected from the separate additive effects. Furthermore, the impacts of 
moderate drinking were stronger in men than in women, but this may be also due to 
differences in true drinking levels.  
 
3. The concentrations of uric acid were higher across the categories of BMI, and 
higher in male moderate drinkers than in abstainers. The findings support the 
hypothesis that oxidative stress plays a pivotal role in many pathologies related to 
heavy alcohol use and obesity, and suggest that oxidative stress is generated early in 
the course of possible health hazards and by rather low degrees of stimuli. In 
premenopausal women, moderate drinking may decrease uric acid, but future 
studies are needed to confirm and understand this phenomenon. 
 
4.  Moderate drinking and excess body weight have markedly influenced the current 
upper reference limits of especially GGT and ALT in men. The effects of BMI and 
drinking should be better taken into consideration when selecting reference 
individuals for the liver enzymes, which associate with heavy drinking and liver 
problems in general, and also with cardiovascular diseases, type 2 diabetes, and the 
metabolic syndrome.  
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ABSTRACT 
 
Aims: Although a wide variety of biomarkers reflecting liver status are known to be 
influenced by excessive ethanol consumption, the dose-response relationships between 
ethanol intake and marker changes have remained less understood.  
 
Methods: Serum gamma-glutamyltransferase (GGT), aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) activities, and ferritin and albumin protein concentrations 
were compared in a large population of heavy drinkers (105 men, 28 women), moderate 
drinkers (781 men, 723 women), and abstainers (252 men, 433 women), who were devoid 
of apparent liver disease. 
 
Results: In heavy drinkers, serum GGT, AST, ALT, ferritin and albumin were all significantly 
higher than in moderate drinkers or abstainers (P < 0.001 for all comparisons). The highest 
incidences of elevated values were found for GGT (62 %) followed by AST (53 %), ALT (39 
%), ferritin (34 %) and albumin (20 %). Serum GGT (P < 0.001), ALT (P < 0.01) and ferritin 
(P < 0.05) in moderate drinkers were also higher than the levels observed in abstainers. 
When the study population was further divided into subgroups according to gender, 
significant differences between moderate drinkers and abstainers in GGT and ALT were 
noted in men whereas not in women. 
 
Conclusions:  The data demonstrate that biomarkers of alcohol abuse and liver function 
may respond to even rather low levels of ethanol intake in a gender-dependent manner, 
which should be implicated in studies on the early-phase interactions of ethanol and the liver 
and in the definition of normal ranges for such biomarkers. 
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INTRODUCTION 
 
Ethanol consumption and associated medical disorders continue to grow in most Western 
countries (Lieber, 1995; Room et al., 2005; Leon and McCambridge, 2006). Therefore, the 
need for more effective diagnostic procedures for detecting problem drinking in its early 
phase has been widely acknowledged (Conigrave et al., 2002). Because nearly all ethanol 
consumed is metabolized by the liver, it is also a primary target of ethanol-induced adverse 
health effects. Previous studies in alcoholic patients have demonstrated several liver-
derived biomarkers, which are associated with excessive ethanol intake and alcoholic liver 
disease (Rosman and Lieber, 1994; Sharpe, 2001; Niemelä, 2007).  Heavy drinkers typically 
show increased activities of serum GGT and transaminases (ALT, AST), whereas upon 
progression of alcoholic liver disease there may be elevations in liver enzymes together with 
abnormally low serum concentrations of hepatic proteins.  
 
Recent studies have indicated a gradual effect of alcohol on GGT enzyme induction, which 
may be initiated at rather low levels of ethanol intake (Hietala et al., 2005).  The status of 
oxidative stress has also been closely linked with serum GGT activities (Whitfield, 2001; Lee 
and Jacobs Jr., 2004; Puukka et al., 2006). However, the dose-response relationships 
between various liver enzymes, proteins, and ethanol intake have, however, continued to be 
poorly known. Comparisons of the different variables between abstainers and moderate 
drinkers have also been limited.  
 
In order to gain further insight on the interpretation of the interactions between ethanol 
intake and biomarkers of liver status, we compared here the serum levels of liver-derived 
enzymes and proteins in individuals with a wide range of ethanol consumption including i: 
abstainers, ii: moderate drinkers and iii: heavy drinkers, who were all devoid of apparent 
liver disease. 
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METHODS 
 
Study protocol 
The sample of heavy drinkers consisted of 133 patients, 105 men (mean age 45 ± 10 years) 
and 28 women (mean age 43 ± 11 years), who had been admitted for detoxification in a 
consecutive manner. All patients underwent detailed clinical examinations and personal 
interviews on the amounts and patterns of ethanol consumption using a time-line follow-
back technique, which indicated a history of continuous ethanol consumption or binge 
drinking, the mean consumption being 110 grams (range 40–540 grams) of ethanol per day 
from the period of 4 weeks prior to sampling. The percentage of patients reporting a mean 
consumption less than 60 g/day or 80 g/day was 5 % and 11 %, respectively. In addition to 
the above, the patients were also advised to sum up their intake from the last one week and 
24 hours, which indicated considerably higher levels of daily ethanol intake from the past 
one week prior to admission. All patients were devoid of any clinical signs of liver 
dysfunction (collateral circulation, oedema, ascites, encephalopathy, spider nevi, anorexia, 
or weakness). 
 
In addition, samples were collected from 1504 moderate drinkers, 781 men (mean age 46 ± 
17 years), 723 women (mean age 45 ± 16 years) and from 685 abstainers, 252 men (mean 
age 49 ± 20 years), 433 women (mean age 49 ± 19 years). All of these subjects were 
apparently healthy volunteers who participated in a Nordic survey for establishing reference 
intervals for common laboratory tests (Puukka et al., 2006).  The mean recent alcohol 
consumption in the population of moderate drinkers had been less than 40 grams per day, 
the maximum amount during the past twenty-four hours prior to sampling being two 
standard drinks (each containing 12 grams of alcohol). The survey excluded individuals who 
had clinical or laboratory evidence of current or recent illnesses or infections, who were 
pregnant, had donated blood during the past five months or had used any prescription drugs 
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during the preceding one week. Smoking had not been allowed for one hour prior to 
sampling.  
 
Measurements of serum gamma-glutamyltransferase (GGT), aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) activities and the concentrations of ferritin and 
albumin were carried out using standard clinical chemical methods. The procedure was 
approved by the institutional review board. Informed consent was obtained from the 
participants and the study was carried out according to the provisions of the Declaration of 
Helsinki. 
 
Statistical methods 
Values are expressed as mean r SD and as 95th-97th percentiles, as appropriate. 
Comparisons between groups were made with Kruskal-Wallis test and Tamhane's T2 post 
hoc test. Upper normal limits were calculated using mean + 2SD if the data came from 
Gaussian distribution or by using nonparametric method if the data came from skewed 
distribution after Dixon´s test to remove outliers, as recommended by Horn and Pesce 
(2003). Correlations were calculated using Spearman's rank correlation. The statistical 
analyses were carried out using SPSS for Windows 15.0 (Chicago, Illinois, USA) software. A 
P-value < 0.05 was considered statistically significant. 
 
 
RESULTS 
 
Table 1 summarizes the values of the various biomarkers of liver status in the groups of 
heavy drinkers, moderate drinkers and abstainers.  Among heavy drinkers, serum GGT, 
AST, ALT activities and ferritin and albumin concentrations were all significantly higher than 
those observed in either abstainers or moderate drinkers (P < 0.001 for all comparisons). 
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Interestingly, in moderate drinkers the activities of GGT (P < 0.001) and ALT (P < 0.01) as 
well as ferritin (P < 0.05) levels were also significantly higher than those in abstainers (Table 
1). When the study population was further divided into subgroups according to gender, the 
alcoholic men showed significantly higher values than both moderate drinkers and 
abstainers in all of the study variables (Table 1). Male moderate drinkers and abstainers 
also differed in their serum GGT (P < 0.001) and ALT (P < 0.05) activities. In women, the 
heavy drinkers also showed the highest values, whereas in comparisons between moderate 
drinkers and abstainers no significant differences were noted (Table 1). 
 
The amount of self-reported ethanol intake correlated significantly with serum GGT (r = 0.50, 
P < 0.001), AST (r = 0.45, P < 0.001), ALT (r = 0.39, P < 0.001), and ferritin (r = 0.46, P < 
0.001). Among the different biomarkers, GGT was found to correlate strongly with AST (r = 
0.42), ALT (r = 0.53), and ferritin (r =0.49), AST with ALT (r = 0.62), and ferritin (r = 0.61), 
and ALT with ferritin (r = 0.46) (p < 0.001 for all) (Table 2). 
 
In order to explore the interpretation of these variables as possible biomarkers of alcohol 
abuse, we also determined their upper normal limits based on the present population of 
abstainers or moderate drinkers (Table 3). Notable differences in the cut-offs based either 
on the use of the database obtained from moderate drinkers or abstainers were found for 
serum GGT, AST, ALT and ferritin. The incidences of observations, which exceeded the 
abstainer-based upper normal limits among heavy drinkers and moderate drinkers, are 
summarized in Figure 1. The highest incidences of elevated values in heavy drinkers were 
found for GGT (62 %) followed by AST (53 %), ALT (39 %), ferritin (34 %) and albumin (20 
%). 
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DISCUSSION     
 
The present study in a large population of subjects with a wide range of alcohol 
consumption indicates that excessive drinking even in individuals without apparent liver 
disease induces the activities of several liver-derived enzymes and elevates the 
concentrations of hepatic proteins, which have recently been linked with defence 
mechanisms towards oxidative stress (Whitfield, 2001; Lee and Jacobs Jr., 2004; Faure et 
al., 2008). Moderate drinkers also show higher enzyme activities than abstainers 
underscoring an early occurrence of the biochemical responses in response to ethanol 
intake. While GGT and transaminase enzymes are also known to specifically increase as a 
result of obesity (Lawlor et al., 2005; Puukka et al., 2006; Alatalo et al., 2008), the presence 
or absence of overweight should not account for such differences here, since the groups of 
abstainers and moderate drinkers showed essentially similar BMIs (24.3 ± 3.5 and 24.0 ± 
2.9, respectively). Obviously, overweight when occurring together with alcohol drinking 
could, however,  aggravate the metabolic burden and hepatic enzyme responses, as 
recently observed for both GGT (Puukka et al., 2006) and ALT (Ruhl and Everhart, 2005a; 
Alatalo et al., 2008). Current BMIs (24.5 ± 3.8) of the heavy drinkers also exhibited similar 
mean levels. Although the relatively small number of observations in the heavy drinker 
group here does not provide enough statistical power for assessing independent effects of 
ethanol drinking and overweight on hepatic enzymes and proteins within this subgroup, it 
should be noted that obesity has been previously found to be a risk factor for cirrhosis in the 
alcoholics (Naveau et al., 1997). 
 
When compared to abstainers, the group of moderate drinkers also showed elevated levels 
of serum ferritin, a marker of stored body iron. Thus, ethanol-related biochemical 
consequences in iron homeostasis may also be expected to occur at rather low levels of 
ethanol consumption. Previously, heavy drinking has been shown to increase ferritin levels, 
and secondary hepatic iron overload is a typical characteristic of alcoholic patients (Fletcher, 
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1996; Whitfield et al., 2001). Recent studies have indicated that even consumption of > 2 
alcoholic drinks/day may be associated with a significant elevation in the risk of iron 
overload (Ioannou et al., 2004). Deposition of excess iron in hepatic tissue is in turn an 
important secondary risk factor for the development of alcoholic liver disease. In 
experimental animals, iron and alcohol have been shown to act in a synergistic manner to 
enhance lipid peroxidation and liver injury (Bacon and Britton, 1990; Tsukamoto et al., 1995; 
Cederbaum, 2003; Harrison-Findik, 2007). Alcohol consumption also increases the risk of 
liver injury in human patients with iron overload (Fletcher et al., 2002). It has recently been 
hypothesized that serum ferritin may be produced in order to sequester catalytically active 
free iron and increases in serum ferritin could actually reflect a defence mechanism, which 
occurs in response to ethanol-induced oxidative stress (Lee and Jacobs Jr., 2004). 
Increased ferritin levels could thereby protect from oxidative stress and consequent 
pathology due to free iron. In a similar manner, the responses in serum GGT, which is 
responsible for extracellular metabolism of glutathione, the main antioxidant in mammalian 
cells, could be linked to protection from reactive oxygen species (Whitfield, 2001; Puukka et 
al., 2006). On the other hand, acetaldehyde, the main oxidative metabolite of ethanol, has 
been previously shown to alter the gene expression of several proteins, such as collagen 
(Parés et al., 1994; Moirand et al., 1995; Niemelä, 2001; Thiele et al., 2005; Purohit and 
Brenner, 2006).  Since ferritin concentration is also under tight genetic control it is also 
possible that its concentration may be affected in a similar way rather than through the 
cellular iron concentration. 
 
The present data also show increased levels of serum albumin among heavy drinkers 
suggesting increased rates of albumin protein synthesis in response to regular ethanol 
intake prior to the development of liver dysfunction, whereas in patients with advanced liver 
disease the rates of hepatic protein synthesis are obviously decreased. Although the 
mechanisms underlying this observation remain unclear it should be noted that previous 
studies in cell cultures have shown elevated hepatic protein synthesis rates as a result of 
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chronic ethanol administration (Potter et al., 1985; Ohtake et al., 1986; Rothschild et al., 
1988). Recently, Tyulina and co-workers (2006) found elevated plasma albumin levels in 
alcoholics, which correlated with elevated protein carbonyls, suggesting that covalent 
modifications of proteins by acetaldehyde could also be associated with albumin protein 
expression among heavy drinkers. Serum albumin is also an important antioxidant agent, 
whereas any structural modification of albumin induced by ethanol metabolites, glucose or 
free radicals has been suggested to impair its antioxidant properties (Faure et al., 2008).  
 
The ethanol-induced biochemical changes in hepatic tissue appear to occur in a gender-
dependent manner. It remains to be established whether such findings would also correlate 
with the differences in the individual susceptibility to tissue damage, which is known to be 
not equal between men and women (Schenker, 1997). It should also be noted that previous 
studies have indicated effects of smoking (Whitehead et al., 1996; Steffensen et al., 1997) 
and coffee consumption (Nakanishi et al., 2000; Ruhl and Everhart, 2005b) on the activities 
of hepatic enzymes. Unfortunately, in this study the possible confounding effects of smoking 
or coffee consumption could not be addressed. Since people who drink heavily usually also 
smoke a lot we cannot rule out the possibility of additional increasing effects of smoking on 
hepatic enzymes among the heavy drinkers. However, in comparisons between the present 
population of moderate drinkers and abstainers, the enzyme activities or protein levels were 
not found to be significantly different between smokers and non-smokers (data not shown). 
In light of recent evidence indicating that coffee drinking could protect against liver injury and 
lead to reduced activities of liver enzymes (Nakanishi et al., 2000; Ruhl and Everhart, 
2005b; Hu et al., 2008), we feel, that the interactions between ethanol intake, smoking and 
coffee consumption clearly warrant further studies in large populations.  
 
Our data also emphasize the view that due to the possible effects of even rather low ethanol 
doses on hepatic enzymes and proteins the clinical interpretations of any ethanol-sensitive 
biomarkers as diagnostic tests in health care need further attention. Current surveys indicate 
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a trend towards permanent increases in GGT activities at population level (Hietala et al., 
2005; Lee et al., 2006; Niemelä, 2007). On the other hand, serum activities of hepatic 
enzymes have recently been suggested to be useful as general indicators of health and 
disease and long term survival (Kazemi-Shirazi et al., 2007; Kim et al., 2008) Therefore, in 
order to improve the discriminative power of any biomarker reflecting liver status, the normal 
ranges should perhaps be re-defined based on databases of healthy individuals who abstain 
from ethanol. Moreover, the possible roles of a wide variety of biochemical markers as 
players in defense mechanisms towards oxidative stress warrant further studies. 
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FIGURE LEGENDS 
 
Figure 1.  
The incidences of elevated values (%) of serum gamma-glutamyltransferase (GGT), 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), and ferritin and albumin 
concentrations in moderate drinkers and heavy drinkers when compared to upper normal 
limits obtained from the population of abstainers. 
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Table 1. Liver enzyme and protein levels in heavy drinkers, moderate drinkers and abstainers. 
 
 Heavy drinkers Moderate drinkers Abstainers 
GGT (U/l)    
All 177 ± 317 (578–1612)1 29 ± 23 (70–97) *** 24 ± 15 (50–64) ***, ††† 
Men 193 ± 347 (949–1664) 34 ± 24 (79–106) *** 26 ± 14 (53–63) ***, †††  
Women 119 ± 158 (561–607) 23 ± 20 (48–79) ** 22 ± 16 (45–68) ** 
AST (U/l)    
All 63 ± 51 (171–208) 24 ± 8 (38–43) *** 24 ± 7 (36–41) *** 
Men 65 ± 49 (160–204) 26 ± 8 (40–45) *** 25 ± 7 (35–43) *** 
Women 55 ± 57 (235–263) 21 ± 7 (33–37) * 23 ±7 (36–41) * 
ALT (U/l)    
All 67 ± 65 (211–273) 25 ± 15 (51–64) *** 23 ± 12 (46–52) ***, ††   
Men 71 ± 68 (220–282) 29 ± 17 (59–73) *** 26 ± 12 (49–58) ***, †  
Women 51 ± 48 (195–214) 20 ± 11 (40–48) *  21 ± 11 (40–49) * 
Ferritin (µg/l)    
All 212 ± 207 (687–777) 100 ± 83 (246–333) *** 70 ± 63 (245–257) ***, † 
Men 258 ± 222 (750–853) 136 ± 90 (332–378) ***  101 ± 72 (257–257) *** 
Women 105 ± 112 (396–465) 65 ± 55 (188–231) 48 ± 45 (184–225) * 
Albumin (g/l)    
All 44 ± 4 (50–51) 41 ± 3 (46–47) ***  41 ± 3 (46–47) *** 
Men 44 ± 4 (50–50) 42 ± 3 (47–48) ***  42 ± 3 (47–47) *** 
Women 44 ± 4 (51–53) 41 ± 3 (45–46) ** 40 ± 3 (45–46) ***  
  
1 mean ± SD (95th–97,5th percentile) (all such values). 
* P < 0.05, ** P < 0.01, *** P < 0.001 when compared to heavy drinkers. 
† P < 0.05, †† P <0.01, ††† P < 0.001 when compared to moderate drinkers. 
GGT, gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine  
aminotransferase. 
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Table 2.  Correlations between study variables.  
 
 GGT AST ALT Ferritin 
AST 0.42 ***    
ALT 0.53 *** 0.62 ***   
Ferritin 0.49 *** 0.61 *** 0.46 ***  
Albumin 0.10 *** 0.11 *** 0.15 *** 0.12 * 
 
* P < 0.05, *** P < 0.001 
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Table 3. Upper normal limits for the study parameters, as based either on the data from abstainers or moderate drinkers.  
 
 
Upper normal limit 
 Men Women 
 Abstainers Moderate drinkers Abstainers Moderate drinkers 
GGT (U/l)1 63 106 (+68 %) 63  79 (+25 %) 
AST (U/l)1 39 45 (+15 %) 41  37 (–9 %) 
ALT (U/l)1 58 73 (+26 %) 49  48 (–2 %) 
Ferritin (ȝg/l)2 274 342 (+25 %) 141  191 (+35 %) 
Albumin (g/l)2 47 48 (+2 %) 46  46 (0 %) 
 
For abbreviations, see Table 1. 
The percentages in brackets indicate the relative change in the upper normal limits in moderate drinkers as compared to abstainers, calculated 
upper normal limits calculated as 97,5th percentile1 or as mean + 2SD2, as required. 
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Figure 1 
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Free radicalslly involved in a variety of medical disorders involving oxidative stress. Although
alcohol abuse and obesity are known to increase serum uric acid, the interactions between moderate
drinking, adiposity, and uric acid metabolism have remained poorly understood. We examined serum uric
acid concentrations from 2062 apparently healthy volunteers (970 men, 1092 women) reporting either no
alcohol (abstainers) or b40 g of ethanol consumption per day (moderate drinkers). The study population was
further classiﬁed according to BMI as follows: b19 (underweight), 19–25 (normal weight), 25–30
(overweight), and N30 (obese). Serum uric acid concentrations in male moderate drinkers were signiﬁcantly
higher, and in females they were lower, than in the corresponding groups of abstainers. In the BMI-based
subgroups, the highest concentrations were found in those who were overweight or obese. Signiﬁcant two-
factor interactions occurred between gender and drinking status (pb0.001) and between gender and BMI
(pb0.02). Serum uric acid also correlated with indices of hepatocellular health (GGT, ALT, AST). The data
indicate distinct gender-dependent impacts of alcohol consumption and BMI on serum uric acid. These
ﬁndings should be applicable to the assessment of oxidative stress status and associated morbidity in alcohol
consumers and individuals with excess body weight.
© 2009 Elsevier Inc. All rights reserved.Recent studies have indicated that the development of metabolic
syndrome, a cluster of cardiovascular disease risk factors, correlateswith
alterations in serum uric acid levels [1,2]. Although the primary
mechanisms of such interactions have not been deﬁned, mounting
evidence has suggested a role for uric acid as an antioxidant owing to its
ability to chelate transition metal ions and to react with biological
oxidants suchashydroxyl radicals [1,3–5].However, high concentrations
of uric acid in circulation may also have pro-oxidant properties [6,7].
Current surveys have indicated that more than half of the
population in the developed world suffers from overweight or obesity
[8,9]. Obesity is largely responsible for the high prevalence of
metabolic syndrome as well as other adverse health effects, such as
nonalcoholic fatty liver disease, which has increased in an epidemic
manner during the past few years [10,11]. Simultaneously, there has
also been a trend toward increasing ethanol consumption and
associated medical disorders [12,13]. Both excess body weight and
heavy alcohol consumption induce oxidative stress, which can lead to
alterations in hepatic lipid, carbohydrate, protein, lactate, and uric acid
metabolism [14]. As yet, little information is, however, available on the, γ-glutamyl transferase; ALT,
se.
).
ll rights reserved.joint effects of alcohol consumption and adiposity on uric acid
turnover. It is also unclear whether the changes in the concentrations
of uric acid in response to oxidative stress represent a protective
response or a primary cause.
To explore further the biological signiﬁcance of alterations in
serum uric acid levels in circulation, we investigated here the
relationships between serum uric acid, ethanol consumption, and
body mass index (BMI) in a cohort of apparently healthy abstainers
and moderate drinkers.
Materials and methods
Study protocol
Subjects in this study were participants in a survey collected for
establishing reference intervals for common laboratory parameters in
Nordic countries and, therefore, they partially overlap with our
previous study on γ-glutamyl transferase (GGT) [15]. Subjects were
recruited following the rules of the Nordic Reference Interval project
(NORIP protocol) [16]. The study population consisted primarily of
hospital personnel and their relatives or acquaintances, of whom 97%
were Scandinavians and 3% of other Caucasian origin. This population
included 2062 apparently healthy volunteers: 970 men, mean (±SD
age 47±18 years, and 1092 women, mean (±SD) age 47±17 years,
classiﬁed as either abstainers (n=643: 241 men, age 49±20 years;
Table 1
Distribution of study participants into BMI subgroups
BMI
b19 19–25 25–30 N30
Men
Abstainers 3 131 97 10
Moderate drinkers 8 390 302 29
Women
Abstainers 21 245 111 25
Moderate drinkers 35 507 136 12
1234 P.I. Alatalo et al. / Free Radical Biology & Medicine 46 (2009) 1233–1238402 women, age 49±19 years) or moderate drinkers (n=1419: 729
men, age 46±17 years; 690 women, age 45±16 years) and further
according to BMI (kg/m2): b19 (underweight), ≥19 and b25 (normal
weight), ≥25 and b30 (overweight), and ≥30 (obese) (Table 1).
Blood samples were collected between December 1999 and
January 2002. Before sampling, all participants received detailed
instructions to avoid any hard physical activity, avoid any blood
donations, and control the time period since the last meal. Samples
were taken in fasting state primarily between 7:00 and 10:00 AM. The
participants were not paid for their contribution.
The health status and the patterns and amounts of ethanol intake
were assessed using speciﬁcally designed questionnaires. Those who
reported no alcohol intake were classiﬁed as abstainers. Moderate
drinkers were individuals by whom the amount of alcohol consumed
was less than 40 g of ethanol/day and the maximum amount of
alcohol during the past 24 h before sampling had been two standard
drinks (each providing 12 g of ethanol). None of the participants
were former alcoholics or individuals with any social or medical
records of heavy drinking and associated medical disorders. The
survey excluded individuals who had clinical or laboratory evidence
of any current or recent illnesses or infections, who were pregnant,
who had donated blood during the past 5 months, or who had used
any prescription drugs during the preceding week. Possible use of
estrogen-containing preparations was also recorded. Smoking infor-
mation from this material indicated that 81% of the individuals in the
present series were nonsmokers, 6% smoked 1–5 cigarettes per day,
and 11% smoked more than 5 cigarettes per day. Smoking
information was missing from 2% of the subjects. Smoking had not
been allowed for 1 h before sampling.
Serum uric acid concentrations; GGT, alanine aminotransferase
(ALT), and aspartate aminotransferase (AST) activities; and blood
glucose, HDL- and LDL-cholesterol, and triacylglyceride levels were
measured using International Federation of Clinical Chemistry-
compatible measuring systems [16–18].
The procedure was approved by the institutional review board.
Informed consentwas obtained fromtheparticipants and the studywas
carried out according to the provisions of the Declaration of Helsinki.Fig. 1. Serum uric acid concentrations (mean±SD) in the study population of 970 men
and 1092 women reporting either no alcohol consumption (abstainers) or moderate
drinking. ⁎pb0.01 compared to the corresponding group of abstainers.Statistical methods
Values are expressed as means±SD. Differences between groups
were determined with Student's t test when comparing two groups or
ANOVAwith Bonferroni post hoc test formultiple comparisons. Factorial
ANOVA was used to investigate the interactions between gender,
drinking status, and BMI on serum uric acid. Before the analyses, the
data on serum uric acid were subjected to square root transformation to
yield nonskewed distributions with homogeneity of variance. Correla-
tions were calculated with Pearson product-moment Correlations
coefﬁcients. The differences between correlations were analyzed with
the Z test for correlation coefﬁcients. Linear regression analysiswas used
to measure proportions of variability. The analyses were carried out
using SPSS 15.0 forWindows statistical software (Chicago, IL, USA). Tests
were considered statistically signiﬁcant at pb0.05.
Results
Serum uric acid concentrations in male moderate drinkers were
signiﬁcantly higher (pb0.01), and in female moderate drinkers lower
(pb0.01), than those in the corresponding groups of abstainers (Fig.
1).When the study populationwas further classiﬁed according to BMI,
the highest concentrations were found in overweight and obese
individuals (Fig. 2). Interestingly, signiﬁcantly higher uric acid
concentrations in male moderate drinkers (335±62 μmol/L) com-
pared to abstainers (313±52 μmol/L) were found in those with
normal weight (pb0.001) and not in those with BMI above 25 kg/m2.
Serum uric acid correlated signiﬁcantly with BMI (r=0.42,
pb0.001), and also with the biomarkers of liver status: GGT
(r=0.41, pb0.001), AST (r=0.32, pb0.001), and ALT (r=0.32,Fig. 2. Serum uric acid concentration (mean±SD) in abstainers and moderate drinkers
as further classiﬁed according to BMI. The highest values were observed in those who
were overweight or obese. BMI b19, underweight; BMI ≥19 and b25, normal weight;
BMI ≥25 and b30, overweight; BMI ≥30, obese. Horizontal lines indicate signiﬁcant
(pb0.05) differences between groups within each drinking category, as assessed by
ANOVA with Bonferroni post hoc test. ⁎pb0.001 compared to the corresponding group
with similar BMI.
Table 2
Correlations between study variables
BMI Uric acid GGT ALT AST Glucose HDL LDL
Uric acid 0.42⁎⁎⁎
GGT 0.32⁎⁎⁎ 0.41⁎⁎⁎
ALT 0.29⁎⁎⁎ 0.32⁎⁎⁎ 0.48⁎⁎⁎
AST 0.21⁎⁎⁎ 0.32⁎⁎⁎ 0.34⁎⁎⁎ 0.58⁎⁎⁎
Glucose 0.32⁎⁎⁎ 0.30⁎⁎⁎ 0.26⁎⁎⁎ 0.23⁎⁎⁎ 0.26⁎⁎⁎
HDL –0.35⁎⁎⁎ –0.34⁎⁎⁎ –0.18⁎⁎⁎ –0.18⁎⁎⁎ –0.01 –0.10⁎⁎
LDL 0.27⁎⁎⁎ 0.23⁎⁎⁎ 0.32⁎⁎⁎ 0.17⁎⁎⁎ 0.22⁎⁎⁎ 0.33⁎⁎⁎ –0.07⁎
Triacylglycerides 0.37⁎⁎⁎ 0.29⁎⁎⁎ 0.27⁎⁎⁎ 0.23⁎⁎⁎ 0.16⁎⁎⁎ 0.31⁎⁎⁎ –0.40⁎⁎⁎ 0.34⁎⁎⁎
HDL, high-density cholesterol; LDL, low-density cholesterol.
⁎ pb0.05.
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.
1235P.I. Alatalo et al. / Free Radical Biology & Medicine 46 (2009) 1233–1238pb0.001), and with blood glucose (r=0.30, pb0.001) and serum
lipids (HDL-cholesterol, r=−0.34, pb0.001; LDL-cholesterol,
r=0.23, pb0.001; triacylglycerides, r=0.29, pb0.001) (Table 2). In
separate analyses for men and women, the correlation between uric
acid and BMI was signiﬁcantly (pb0.02) stronger inwomen (r=0.38)
than in men (r=0.27) (Fig. 3) and also when computing partial
correlations controlling for drinking status (women, r=0.40; men,
r=0.26). In this study, smoking status was not signiﬁcantly associated
with serum uric acid levels.
Fig. 4 illustrates the relative differences in serum uric acid levels
between the study groups of men and women using the correspond-
ing population of abstainers with normal weight as baseline. Among
abstainers presenting with obesity the mean uric acid levels were 14%
(men) and 37% (women) above this baseline, whereas in moderate
drinkers the corresponding difference was 24% for both genders.
Factorial ANOVA was subsequently used to assess the relative
importance of the various combinations of explanatory variables on
serum uric acid. While the three-factor interaction between BMI,
drinking status, and gender was not signiﬁcant, joint effects between
gender and drinking status (pb0.001) and between gender and BMI
(pb0.02) were observed. In additional gender-speciﬁc two-factor
analyses the interaction between BMI and drinking status was nearly
signiﬁcant (p=0.056) among men but not among women.
Increasing age has also been suggested to affect the concentrations
of uric acid. Multiple regression analyses on the effect of age in this
study indicated that age accounts for nearly 9% (multiple R2=0.089)
of the variation in women but for only 0.1% (multiple R2=0.001)
among men. Uric acid concentrations were signiﬁcantly higher in the
subgroup of postmenopausal (276±58 μmol/L) compared to pre-
menopausal (238±50 μmol/L) women (pb0.001). Premenopausal
moderate drinkers not using any estrogen medication and having BMI
b25 showed lower serum uric acid levels (226±46 μmol/L, n=93)
than their abstaining counterparts (242±34 μmol/L, n=41;
p=0.024), whereas no such differences were seen in correspondingFig. 3. Scatter plots of the correlations between BMI and uric acid in men and womcomparisons among overweight premenopausal or postmenopausal
groups, or among estrogen users.
Discussion
This cross-sectional survey among a large population of apparently
healthy abstainers and moderate drinkers indicates distinct gender-
dependent impacts of increased body weight and alcohol drinking on
serum uric acid, which has recently been closely linked with oxidant
stress status in humans [1,5]. The concentration of serum uric acid is
inﬂuenced bynitric oxide (NO) and peroxynitrite production and plays
a pivotal role in the human antioxidant defense systems through its
ability to scavenge free radicals [4,5,19–21]. Uric acid also prevents the
degradation of extracellular superoxide dismutase [22], an important
enzyme maintaining normal NO levels and endothelial function.
Both excessive ethanol consumption and adiposity readily induce
oxidative stress in vivo. Although the effects of alcohol abuse [23–25]
and obesity [1] on serum uric acid levels have been previously
acknowledged, as yet the early phase interactions between uric acid,
ethanol intake, and adiposity have received less attention. The
biological signiﬁcance of alterations in uric acid levels under such
conditions has also remained obscure. It is tempting to speculate that
by acting as an antioxidant uric acid could counteract oxidative stress
and endothelial dysfunction, which, based on the present data, could
occur even in apparently healthy individuals with adiposity and
alcohol consumption. Recent studies have suggested a role for uric acid
as a mediator of cardiovascular and renal diseases, metabolic
syndrome, and type 2 diabetes [26–31]. Although hyperuricemia has
in general been regarded as a cardiovascular risk factor [32,33],
conﬂicting data also exist. Experimental administration of uric acid
induces a signiﬁcant increase in serum free radical scavenging capacity
in healthy volunteers [34] and improves endothelial function in the
forearm vascular bed of smokers and in patients with type 1 diabetes
[35]. Elevated uric acid concentrations are also associated withen. A signiﬁcantly stronger correlation was observed among women (pb0.02).
Fig. 4. Relative changes (%) in mean serum uric acid in the study groups of men and women. The mean activity obtained from the corresponding group of abstainers with normal
weight is used as baseline. For weight group BMIs, see the Fig. 2 legend.
1236 P.I. Alatalo et al. / Free Radical Biology & Medicine 46 (2009) 1233–1238increased serum antioxidant capacity and reduced oxidative stress
during acute physical exercise among healthy subjects [36].
Interestingly, the present data indicate striking gender differences
in uric acid responses. Whereas moderate alcohol consumption seems
to be associated with low uric acid concentrations among women,
men seem to show the opposite. Previous studies have suggested that
sex steroids play a key role in the regulation of oxidant stress status in
vivo [37–40]. In accordance with the present ﬁndings, Gao et al. [41]
recently found that a greater intake of added sugars or sugar-
sweetened drinks was associated with high plasma uric acid
concentrations in men but not in women. Pitocco and coworkers [5]
have reported that the initial increase in oxidative stress coincides
with a reduction in plasma levels of uric acid in women with type 1
diabetes. Interestingly, uric acid seems to increase in menopause [42],
during which the relative cardioprotection of premenopausal women
compared to men of corresponding age is also lost [43]. Uric acid can
improve NO-mediated vasorelaxation in arteries, and the cardiovas-
cular risk status of women may also be linked with NO owing to the
fact that it is inducible by estrogen [44]. Alcohol intake can induce
both pre- and postmenopausal estrogen [45,46] and thus possibly
potentiate NO and lead to lower uric acid levels, as noticed here
particularly among premenopausal normal weight women.
Unchanged uric acid in the corresponding group of postmenopausal
women could be due to unresponsiveness of estrogen receptors.
Indeed, decreased downstream signaling through estrogen receptors
has previously been proposed to account for the lack of vascular
beneﬁts of hormone therapy in agingwomen [44,47]. In overweight or
obese women excess body weight seems, however, to overpower the
impact of moderate alcohol intake. It remains to be established
whether estrogen induction by moderate ethanol intake could also be
associated with possible beneﬁcial cardiovascular effects speciﬁcally
in normal weight premenopausal women. It could also be argued that
the decrease in uric acid and antioxidant defense could render women
more susceptible to oxidative stress in other tissues, such as adverse
effects of ethanol in the liver. Indeed, women are known to have a
greater propensity than men for ethanol-induced tissue damage at
more than moderate drinking levels.
Unfortunately, in this work the preferred type of alcoholic beverage
consumed was not recorded systematically enough to allow beverage-
speciﬁc analyses of the data. Current statistics from corresponding
Scandinavian populations have indicated that the share of strong
alcohols is approximately 15–20% of the total alcohol consumption
among men and about 10% in women, whereas mild beverages,
primarily beer, is responsible for more than half of the total consump-
tion in both genders. The rest of the consumption is mostly wine, the
proportion of which is slightly higher among women (20–30%) than
among men (15–20%). Although we feel that the type of alcoholic
beverage consumedby themoderate drinkers in this study is unlikely tohave accounted for the observed changes in serum uric acid, this issue
should be a subject of future studies in large samples of individualswith
varying levels of drinking different types of alcoholic beverages.
Similarly, in light of recent studies indicating a protective effect of
coffee consumption on ethanol-induced oxidative stress in hepatic
tissue, which may also occur in a gender-dependent manner [48–50],
studies on the associations between coffee consumption and uric acid
metabolism seemwarranted.
The present data further indicate signiﬁcant correlations between
uric acid and indicators of hepatocellular health. Apparently, alcohol
drinking occurring together with excess caloric intake is a potent
inducer of hepatocellular oxidative stress. Previous studies in experi-
mental liver diseases have indicated that high-fat diets reproduce
many of the features found in nonalcoholic steatohepatitis and
administration of high-fat diets together with ethanol results in
enhanced oxidative stress and more severe liver injury [51]. The
ethanol-inducible cytochrome enzymeCYP2E1mayalso be induced by
obesity, owing to free fatty acids serving as substrates [52,53]. We
previously reported that alcohol drinking and obesity increase serum
GGT in an additivemanner [15]. GGT is responsible for the extracellular
metabolism of glutathione, the main antioxidant in mammalian cells,
and GGT enzyme induction may be speciﬁcally associated with the
generation of reactive oxygen species [54–58]. Interestingly, serum
ALT, which also seems to readily respond to both ethanol intake and
adiposity [59–61], has recently been suggested to be a good indicator of
overall health in the context of obesity, metabolic syndrome, and
cardiovascular disease [11]. Obviously, the links between serum uric
acid, oxidative stress, and biomarkers of liver status, which associate
with various biochemical and anthropometric features of the meta-
bolic syndrome [62,63], also warrant future studies.
Our ﬁndings are also in accordance with the view that uric acid
could serve as a clinical biomarker of oxidative stress provided that
the effects of obesity and ethanol intake would be carefully controlled
in the deﬁnition of normal ranges for such measurements. It may be
recommended to use databases of abstainers with normal weight as a
reference or, alternatively, BMI-based reference intervals. Combina-
tions of uric acid and liver enzyme levels could possibly be used to
develop more accurate models to evaluate biological responses to
oxidative stress and associated pathophysiologies in the human body.
Conclusions
This study indicates signiﬁcant interactions between gender, BMI,
alcohol consumption, and serum uric acid, which may be associated
with the status of oxidative stress in such individuals. Future
population studies addressing the prognostic and clinical implications
of such responses andwhether itmight be necessary to formulate BMI-
based recommendations for uric acid normal ranges seemwarranted.
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Abstract
Background. Unexplained liver enzyme activities are often found in health screening programs and constitute an increas-
ingly common cause for referral to specialized clinics. Recent studies have indicated that both excess body weight and 
alcohol consumption may lead to metabolic aberrations which are readily reflected in the activities of liver enzymes in 
circulation.  Materials and methods.  We compared various laboratory markers and their upper normal limits in relation to 
information on alcohol consumption and BMI in a large population of apparently healthy individuals collected from Nor-
dic countries.  Results. Based on the data obtained from normal weight abstainers (BMI 19–25 kg/m 2) the upper normal 
limits in men should be 50 U/L for ALT, and 45 U/L (40 years) and 70 U/L (40 years) for GGT, while the current 
recommendations are 70 U/L, 80 U/L, and 115 U/L, respectively. Already in comparisons between normal weight abstainers 
and corresponding moderate drinkers notable impacts (14% – 74%) on upper limits for these analytes were seen, which 
further grew when adiposity occurred together with alcohol drinking (75% – 186%, BMI 27 kg/m 2). In addition to 
liver enzymes, similar changes were also found for uric acid. Conclusions. Alcohol consumption and excess body weight 
even in apparently healthy individuals have a significant influence on liver enzyme activities, which may be due to a cumu-
lative oxidative stress burden. The metabolic changes induced by adiposity or ethanol intake should be considered in the 
definition of normal ranges for all laboratory parameters sensitive to oxidative stress. 
Key Words: Alanine aminotransferase , aspartate aminotransferase , body mass index , ethanol, gamma-glutamyltransferase , normal 
limit, overweight , uric acid 
Introduction
During the past few decades several new challenges 
for health care services have emerged. The rapidly 
increasing percentage of individuals with excess body 
weight constitutes a major threat in all Western coun-
tries. In the European Union approximately 50% of 
the population was either overweight or obese in 
2003 [1]. Simultaneously, the total per capita ethanol 
consumption and associated medical disorders have 
been growing [2–4]. Thus, obesity-related health 
problems are also more and more likely to co-exist 
with ethanol consumption. 
In laboratory medicine increasing national and 
international mobility has created a need for harmo-
nization of reference intervals. Historically, because of 
a wide variety of differences in both methods and 
populations, laboratories have been advised to estab-
lish their own reference intervals for each analyte. This 
is, however, a highly demanding and costly process for 
a single laboratory and, therefore, reference intervals 
obtained from literature or from small sample sizes 
are often used. As a consequence, considerable varia-
tion between laboratories may also occur. Recently, 
along with advances in methodological consensus, the 
production of common reference intervals has become 
a potential approach to overcome these problems. The 
Nordic Reference Interval Project (NORIP) [5] 
showed that partitioning of the reference intervals 
by country (i.e. Denmark, Finland, Norway and 
Sweden) was not necessary [6]. This project resulted 
in recommendations for common reference intervals 
for 25 biochemical parameters frequently measured 
Sc
an
d 
J C
lin
 L
ab
 In
ve
st 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Sw
et
s I
nf
or
m
at
io
n 
Se
rv
ic
es
 o
n 
07
/2
6/
10
Fo
r p
er
so
na
l u
se
 o
nl
y.
 Alcohol, BMI, and laboratory markers 105
in serum [7]. In addition to analytical and method-
ological data a number of demographic characteristics 
in relation to this reference population were system-
atically documented [8]. 
In the present study we explored the effects of 
alcohol consumption and excess body weight on the 
reference intervals using the database from the 
NORIP material. 
Materials and methods 
Study protocol
The main characteristics of the NORIP population 
have been previously described in detail [8]. Origi-
nally, blood samples from over 3000 healthy indi-
viduals were collected by Nordic routine clinical 
biochemistry laboratories together with information 
on sex and age, and various other factors such as 
drinking and smoking habits, medication, and body 
mass index (BMI, kg/m 2). In this study, alcohol con-
sumption was classified in categories of 0 measures 
(abstainers), 1–21 measures (moderate drinkers) and 
21 measures of alcohol/week, where one measure 
is equivalent to 12 g of pure ethanol. The data from 
Sweden were excluded due to non-standardized 
assessment of alcohol consumption [8]. In the 
remaining population 31.0% were abstainers and 
67.5% moderate drinkers. Individuals who reported 
more than 21 measures of alcohol per week (0.5%) 
or had not answered (1.0%) were not included in the 
analyses. The data gathered on smoking habits indi-
cated that 80% were non-smokers, 6% smoked 1–5 
cigarettes/day, and 11% smoked 5 cigarettes/day 
(3% had not answered). A total of 19% had used 
medication other than the P-pill or estrogen prepara-
tions during the preceding week (76% had not used 
medication, 5% had not answered). In men 1% were 
underweight (BMI 19 kg/m 2), 54% normal weight 
(BMI 19–25 kg/m 2), 41% overweight (BMI 25–30 
kg/m2), and 4% obese (BMI 30 kg/m 2). In women 
the corresponding percentages were 5%, 69%, 22%, 
and 4%, respectively. 
Statistical methods 
Data exclusions, calculations of reference limits, and 
group stratifications were carried out following 
the NORIP protocol [7]. Outliers were detected 
by Dixon’s test (performed manually to enable suc-
cessful handling of clusters of two or more outliers) 
for each reference data set separately, as proposed 
by IFCC [9]. The influence of the drinking habit 
(predictor variable) was assessed by linear regression 
in a model with each analyte as the dependent vari-
able, and by adjusting for body mass index (BMI), 
age, smoking habit and medication. For skewed ana-
lytes logarithmic transformation was used to yield 
symmetrical distributions. The analyses were made 
separately for groups with different reference inter-
vals and further according to sex. A  p-value 0.05
was considered statistically significant. The analyses 
were carried out using Analyse-it 2.11 for Microsoft 
Excel (Analyse-it Software, Ltd., Leeds, UK) and 
SPSS 15.0 (SPSS Inc., Chigaco, IL, USA) statistical 
software. 
Results
As noted previously, more than half of the analytes 
included in the NORIP protocol differ significantly 
between the individuals representing BMI 27 kg/m 2
and 27 kg/m 2 [10]. For such parameters the data 
on reference limits in subgroups classified according 
to both BMI and alcohol drinking are summarized 
here in Table I. The most striking changes (10%)
between upper normal limits derived from normal 
weight abstainers and moderate drinkers with BMI 
27 kg/m 2 were observed in alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), 
total cholesterol, creatinekinase (CK), gamma-glu-
tamyltransferase (GGT), glucose, HDL-cholesterol, 
triglycerides, and uric acid. Drinking habit was found 
to be a statistically significant independent positive 
predictor variable of GGT activity, total cholesterol 
(50 years) and uric acid in men, and of HDL-
cholesterol concentration in both men and women. 
When comparing the upper normal limits between 
normal weight abstainers and the corresponding 
group of moderate drinkers, clinically relevant alter-
ations were observed for GGT and ALT. Age, smok-
ing habit or use of medication were not found to 
significantly influence the above associations in this 
population. 
The relative risks for abnormal findings as a func-
tion of drinking status were further assessed by com-
paring the incidences of abnormal values in alcohol 
drinkers to those found in normal weight abstainers 
(Figure 1). Particularly in men there was a gradual 
increase in the relative risks for higher liver enzyme 
activities (ALT, AST, GGT) from normal weight 
abstainers to moderate drinkers, and from overweight 
abstainers to corresponding moderate drinkers. When 
the reference limits obtained from normal weight 
abstainers were used as cut-offs the increase in rela-
tive incidence of abnormal values from normal weight 
abstainers to overweight moderate drinking men was 
up to 3–7-fold, being lowest for AST and highest for 
GGT. A similar pattern and a more than 3-fold 
higher relative risk was also found for uric acid. In 
addition, changes in relative risks were seen in serum 
lipid profiles, although the changes were less promi-
nent than those for liver enzymes (Figure 1). 
The upper normal limits derived from the total 
NORIP population and from the subpopulation 
including only normal weight abstainers are 
compared in Table II. It appears that up to 82% 
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increase in case of GGT and 40% in ALT may 
be brought about into currently recommended 
upper normal limits by these factors reflecting life 
style.  
Discussion
The present study supports the view that excess body 
weight and alcohol drinking create additive effects on 
several laboratory parameters, especially on liver 
enzymes. Due to the high incidence of both adiposity 
and alcohol drinking in our society, these conditions 
are expected to create a major burden to health care, 
which should also be reflected in the criteria used for 
acknowledging normality or abnormality in labora-
tory values. 
Recent Nordic Reference Interval Project 
(NORIP) introduced a large population of appar-
ently healthy individuals with well-established demo-
graphic characteristics [8], which allow the 
classification of the material according to both BMI 
and drinking status. The establishment of subgroup-
specific reference intervals is, however, a complex 
task. Continuous variables such as BMI are subject 
to arbitrary divisions, which can result in the over-
looking of clinically important differences. Alcohol 
consumption in turn is commonly underreported in 
all alcohol-related questionnaires. The present mate-
rial is, however, unlikely to include significant 
amounts of problem drinkers, since individuals 
reporting over 21 measures/week or over 2 measures 
in the last 24 hours were excluded. It should also be 
noted that the levels of safe alcohol consumption 
may vary between individuals. In Finland the limits 
of 24 measures per week for men and 16 for women 
have been previously set for hazardous drinking [11], 
although adverse health effects are sometimes known 
to follow from even lower levels of consumption 
[12,13]. 
In order to avoid the problems related to hetero-
geneity of reference populations a single population 
with strengthened inclusion criteria could be used to 
produce the normal limits. The present data suggest 
that the group of normal weight abstainers should be 
selected for such purposes in case of several variables 
sensitive to ethanol consumption, excess body weight 
and oxidative stress. In the total NORIP population 
the proportions of abnormal values (compared to the 
theoretical 2.5% in normal weight abstainers) would 
be 8.2%, 7.2% and 5.3% in men for GGT, ALT and 
AST, respectively. We feel that in case of liver func-
tion assessment lower cut-offs would yield benefits 
that are greater than the possible expenses caused by 
increased frequency of abnormal values. 
First, the detection of early changes in liver 
enzyme activities may be important for the early 
diagnosis of alcohol-related health problems 
[14]. At least before the full onset of an epidemic 
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although advanced histological damage due to 
NAFLD can al` so be present without any alert 
[19,20]. Recent surveys have shown that nearly 70% 
of aminotransferase elevations are likely to be 
explained by factors associated with obesity [21]. 
The present data suggest that for ALT the upper 
normal limits based on normal weight abstainers 
should be 50 U/L instead of 70 U/L, as derived from 
the total NORIP population. A decrease in ALT cut-
offs could possibly yield additional clinical signifi-
cance through the fact that in routine clinical work 
the level of aminotransferases twice the normal is 
frequently used as decision-making point for liver 
biopsy in order to rule out the most severe liver dis-
eases, as well as to distinguish patients needing the 
closest follow up [14,22,23]. 
Third, a number of epidemiologic studies argue 
against the escaping levels of upper normal limits. 
Liver enzyme activities have recently been linked not 
only to hepatocellular health but also to diabetes, the 
development of metabolic syndrome and cardiovas-
cular diseases (CVD) [24]. Rather than being a 
sequela of any apparent tissue pathology, liver enzyme 
changes also seem to have predictive value. Slightly 
increased GGT activities are associated with increased 
risk of diabetes and CVD [25,26]. Very recently 
Goessling et al. [27] reported that ALT, even within 
its normal range (40 U/L), could predict diabetes 
and metabolic syndrome. In addition, AST was 
Figure 1. Relative risks for abnormal values in different study groups. The incidence of values over the normal weight abstainer-based
upper normal limit (for HDL-cholesterol below the lower normal limit of 1.07 mmol/L (women) and 0.88 mmol/L (men)) was compared
to the theoretical reference incidence of 2.5%. The signiﬁ cances indicating positive prediction by drinking habit only are marked as follows: 
∗∗∗p 0.001; ∗∗p 0.01, and ∗p 0.05. All models were adjusted for BMI, age, smoking habit and medication.
of obesity, experts considered roughly 70% of cases 
of increased GGT activity to be explained by excess 
alcohol consumption. In NORIP recommendations 
the upper normal limits of GGT activity for men 
were 80 U/L for those 40 years of age and 115 
U/L for those 40 years of age, whereas the present 
data indicate that for normal weight abstainers the 
corresponding figures should be set at around 45 
U/L and 70 U/L, respectively. On the edge of age 
40 especially striking discrepancies between the 
early phases of liver pathology and interpretation of 
liver enzyme activities may be expected to occur. 
Although there currently are rather specific new 
biomarkers (such as CDT) for revealing alcohol 
abuse [15], it should be emphasized that they are 
largely ordered under suspicion and their sensitivity 
is not high enough for screening. 
Second, monitoring early changes in liver enzymes 
is crucial in the assessment of non-alcoholic fatty 
liver disease (NAFLD), which has recently been 
recognized as the hepatic manifestation of obesity 
and the metabolic syndrome with the prevalence of 
20–30% in general population and up to about 85% 
among obese individuals [16]. The disease consti-
tutes a spectrum of liver injuries ranging from ste-
atosis (fatty liver) to steatohepatitis (NASH), which 
can further progress to cirrhosis [17,18]. The only 
clinical evidence of these conditions may be mild to 
moderate elevations in aminotransferase levels, 
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indicative of future diabetes. These associations were 
independent of the other common measures of adi-
posity and metabolic derangements, such as interim 
weight change, and baseline BMI or glucose levels. 
Accordingly, Ioannou [28] recently concluded that 
ALT activities should no longer be considered solely 
as a marker of an underlying liver disease, but also 
as a biomarker of ectopic fat deposition. 
Recent findings have emphasized injuries due to 
free oxygen radicals and oxidative stress as the under-
lying cause for liver enzyme elevations [29]. Both 
alcohol consumption and excess body weight induce 
oxidative stress, and it appears that especially among 
obese individuals this could occur in a more striking 
manner as a result of ethanol intake [30]. Oxidative 
stress is also thought to play a causal role in the 
development of cancer and neurodegenerative 
diseases, and in aging (Figure 2) [31,32]. Interest-
ingly, the cytochrome CYP2E1 enzyme induction, 
which is one of the central pathways responsible for 
the ethanol-generated state of oxidative stress in 
hepatocytes, may also be achieved by obesity alone 
due to free fatty acids serving as substrates [33]. 
Since GGT plays a crucial role in maintaining intra-
cellular levels of glutathione, the main antioxidant in 
mammalian cells, increases in its activity may be a 
generalized early sign of counteracting mechanisms 
to protect hepatocytes against oxidative damage 
[34,35]. Higher ALT levels in conjunction with alco-
hol consumption and adiposity may, in turn, be asso-
ciated with oxidative stress related to increased fatty 
deposition in the liver [34]. Accordingly, in this study 
liver enzyme activities showed a gradual increase in 
upper normal limits and relative risks from normal 
weight abstainers to overweight moderate drinkers. 
Intriguingly, similar changes were observed in uric 
acid, which has also been proposed as an index of 
oxidant stress status [36,37]. 
The present data also show changes in serum 
lipid profiles as a result of moderate drinking. Several 
studies have emphasized possible positive impacts 
of moderate ethanol intake especially on HDL-
cholesterol, and subsequently, on cardiovascular 
mortality [38,39]. It should be noted, however, that 
the changes in liver enzymes and associated relative 
risks may exceed the benefits observed for serum 
lipids. Such comparisons apparently warrant future 
studies in large materials representing different body 
weights. 
In the present material, age, smoking habits and 
medication were not found to confound the associa-
tions reported. It should be noted, however, that in 
the NORIP material only a few individuals were 
smokers or used any type of medication and  therefore
Table II. Comparison of upper normal limits based on the total Nordic Reference Interval Project (NORIP) material [7] and from normal 
weight abstainers.
Analyte Unit Gender Age
Upper normal limit
NORIP suggestions
Normal weight; 
Abstainers
Alanine aminotransferase U/L F 18 45 37
M 18 70 50
Aspartate aminotransferase U/L F 18 35 40
M 18 45 40
Gamma-glutamyltransferase U/L F 18–39 45 38
40 75 75
M 18–39 80 44
40 115 69
Cholesterol mmol/L FM 18–29 6.1 6.0
30–49 6.9 6.6
50 7.8 8.0
HDL-cholesterol mmol/L F 18 2.7 2.7
M 18 2.1 2.1
Triglycerides mmol/L FM 18 2.60 2.27
Uric acid μmol/L F 18–49 350 325
50 400 378
M 18 480 446
Figure 2. Illustration of the mechanisms and outcomes potentially linking alcohol consumption and excess body fat.
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in light of recent findings indicating synergism 
between alcohol consumption and smoking with 
respect to liver enzymes [40], further studies appear 
also warranted to evaluate such effects in individuals 
with different levels of smoking and ethanol intake. 
In conclusion, the material gathered by the NORIP 
project has provided an excellent tool for testing cut-
offs between normality and abnormality in laboratory 
markers, but also to retrospectively evaluate the refer-
ence intervals already in use. It appears that the effects 
of moderate alcohol consumption and excess body 
weight on several laboratory parameters need further 
attention. While it may be argued that narrower inter-
vals would translate into a high percentage of false 
positives [41], in light of our observations, many of 
the false positives may actually be true positives, since 
the presence and consequences of a harmful etiology 
are identifiable. In the end, abnormal values are those 
that ultimately prompt the action. 
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